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A B S T R A C T
A  plasmid vector was constructed which allowed for the in-frame insertion of peptide-encoding 
sequences at the 3’ terminal of the Escherichia coli (E . coli) heat-labile enterotoxin B-subunit 
(L T -B ) structural gene. Several synthetic oligoncleotides, encoding various B and T  cell 
epitopes from other proteins, were ligated into this vector. Th e  sequence across the junctions 
of these novel plasmid constructs was determined and found to be as predicted. The chimeric 
fusion proteins expressed by these constructs were characterised in vitro by S D S-PAG E, 
Western blotting and G M1-linked ELISA. All the fusion proteins were shown to behave like native 
L T -B  in that they were transported to the periplasmic space when expressed in E. coli. In 
addition they formed pentamers which dissociated into their constituent monomers upon boiling. 
Furthermore, the pentameric forms were found to retain G,.,,-binding properties as determined 
by G,,,-linked ELISA.
Some of these plasmids, expressing L T -B  fusion proteins containing T  cell epitopes, were 
transferred into an aromatic-dependent attenuated strain of Salmonella typhlmurium SL1344, 
and these strains were used to inoculate mice. A weak serum antibody response to one of 
these epitopes was demonstrated. However, a consistent in vitro T  cell response to these 
epitopes could not be detected.
Another of the fusion proteins, termed LT-B69, was partially purified by ion-exchange 
chromatography and used to inoculate mice intranasally. Mice immunised in this way developed 
serum antibodies against L T -B  and P.69 (an important Bordetella pertussis antigen). 
Additionally, LT-B-specific and P.69-specific antibody secreting cells could be detected in their 
lungs. There was some evidence to suggest that these mice were slightly protected against 
colonisation by B. pertussis after an aerosol challenge with live organisms, compared to the 
levels of colonisation in a control group.
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C H A P T E R  1
Intrpductkpn
1.1 Some Introductory comments on the mucosal Immune system
The immune system can mount both systemic and local responses. There are many significant 
differences in the type of stimulus required to provoke the two types of immune response and 
in the nature of the immunity generated. In simple terms, the systemic response gives rise to 
serum antibody and effector T  cells which mediate a wide range of processes: for example, 
opsonisation of bacteria, clearance of viral infections and transplant rejection. Such responses 
can be efficiently stimulated in experimental animals by the administration of pg amounts of 
antigen parenterally (e.g. intraperitoneally, intramuscularly) if strong adjuvants are used (such 
as complete Freund's adjuvant), leading to long-lasting immunological memory. Vaccination of 
humans usually requires multiple inoculations because powerful adjuvants like C F A  cannot be 
used as they cause unacceptable side effects (e.g. granuloma formation).
In contrast, mucosal responses are difficult to induce and are often of short duration. 
Mucosal immunity is mediated in large part by secretory IgA (slgA), mainly produced locally by 
plasma cells adjacent to the mucosal epithelium, although in rats significant amounts of the 
slgA present at mucosal surfaces are derived from serum directly or indirectly via bile (Ortans 
el al., 1978, Halsey et al., 1980). In man, the derivation of slgA from bile is thought to be less 
important because human hepatocytes do not express secretory component, an essential 
element in the secretion of IgA (described in detail later). Delacroix (1985) estimated that 
human bile contributes about 1mg/kg/day to gut IgA, whereas locally secreted IgA exceeds 
30mg/kg/day. It has been calculated that IgA synthesis is responsible for 2/3 of total human 
immunoglobulin production (Mestecky & M cGhee, 1987).
There are numerous sites of IgA secretion -  the gut, lungs, mammary, salivary and lacrymal
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glands. It is worthy of note that in the human small intestine there are about 10<o 
immunoglobulin producing cells per metre, which is comparable to the 2.5 x 1010 estimated to 
be present in bone marrow, spleen and lymph nodes collectively (Brandtzaeg etal., 1987). It 
has been demonstrated that there is considerable circulation of immunocompetent cells 
between the various mucosal sites. For example, Mestecky eta!., (1978) showed that after oral 
immunisation of mice with killed Streptococcus mutans, specific slgA in salivary and lacrymal 
secretions could be detected without an elevation in serum antibody titres. Similarly, McDermott 
and Bienenstock (1979) found evidence that murine B plasma cell precursors migrated into 
intestinal, respiratory and genital tissues after stimulation by antigen. These and other findings 
led to the postulation of the existence of a "common mucosal immune system” (Bienenstock 
4  Befus, 1980). Further evidence supporting this concept was provided by DeSousa (1981), 
who demonstrated that mouse lymphocytes derived from mucosal tissues, when transferred to 
a syngeneic animal, have a tendency to return to the tissue of origin. If the common mucosal 
immune system is a reality then it raises the exciting possibility of oral immunisation being able 
to protect against infection at distal mucosal sufaces. Such vaccines would possess a number 
of intrinsic advantages over more conventional vaccines which are outlined below.
1.2 Advantages of vaccines designed to stimulate mucosal Immunity
Th e  majority of pathogens of man (and other animals) be they bacterial, viral or protozoal, 
cause disease by initially colonising or entering via mucosal surfaces. Thus an extremely 
important advantage of any vaccine which can elicit a protective mucosal immune response 
is that it may prevent infection perse. This is very significant for a number of reasons. In some 
acute viral infections, such as the common cold, there is a rapid onset of symptoms which are 
experienced before any secondary systemic response can be mounted. In addition, such local 
mucosal immunity would prevent the establishment of a carrier population. This would eliminate 
reservoirs of infection. Also, a mucosal immunisation strategy, by reducing or eliminating the
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carrier population, would increase the likelihood of achieving "herd immunity", inhibiting the 
development of an outbreak of disease into an epidemic.
Equally important is the observation that, for many diseases, mucosal immunity is simply 
more relevant for protection than systemic immunity. A  good illustration of this phenomenon 
is cholera. There are estimated to be nearly 8 million cases of cholera world wide each year, 
resulting in 124,000 deaths (Black, 1986). The  disease is caused by infection with Vibrio 
choierae, an organism which in man is essentially non-invasive. Parenteral inoculation with 
whole-cell cholera vaccines generates high titres of anti-bacterial serum antibodies in man 
(Svennerholm & Holmgren, 1986a). However, protective levels in the gut are maintained for 
only a short time. The parenteral vaccine is not very effective at protecting people travelling to 
areas where cholera is endemic (Behrens, 1991). In contrast, certain killed V. choierae whole 
cell/subunit combination vaccines given orally provide solid protection for a comparatively long 
period (Svennerholm & Holmgren, 1986a). Yet another important advantage is that as stated 
earlier, if the concept of common mucosal immune system is correct, one oral inoculation might 
be able to provide protective immunity at all mucosal surfaces.
There are also a number of very practical advantages which accompany the stimulation of 
mucosal immunity. Principal among these is that the oral or intranasal routes of inoculation, 
which best elicit mucosal responses, obviate the need for injections performed by medically- 
trained personnel. Such an approach also avoids the risk of transmission of blood-borne 
agents, such as hepatitis B  virus or HIV. The  take-up rate for this sort of vaccine would be 
higher than for a corresponding vaccine given parenterally, as many people dislike injections. 
In addition, although there is little experience of oral or intranasal immunisation, it seems 
probable that these routes of inoculation would be safer than conventional routes 
(lipopolysaccharide, for instance, is comparatively harmless when given orally but can be fatal 
if given intravenously).
Finally, there is some evidence that the ability to mount secretory immune responses arises 
in human infants in advance of the capacity to mount systemic responses (McGhee & 
Mestecky, 1990). Thus it may be possible to protect very young children against diarrhoeal
3
diseases (which are a major cause of infant mortality in less-developed countries) by the use 
of a vaccine which induces secretory responses. In the light of these advantages it is important 
to understand as fully as possible the immune mechanisms operating at mucosal surfaces. 
These are outlined below.
1.3 The structure and function of the mucosal immune system
1.3.1 Historical background
The importance of the mucosal immune system was first demonstrated as long ago as 1891, 
when Paul Ehrlich showed that oral immunisation with ricin could protect rabbits against the 
necrotic effects caused when ricin was introduced into the conjunctival sac (Mestecky & 
McGhee, 1989). Research in 1922 by Vaillant, which compared the efficacy of oral versus 
subcutaneous inoculation with a killed Salmonella typhi vaccine, showed that superior 
protection resulted from the oral route of immunisation (Gay, 1924), underlining the significance 
of local immunity. Subsequently, strenuous efforts have been made to obtain an oral vaccine 
against a number of pathogens, most notably V. cholerae, S. typhi, Shigella dysenteriae. 
Streptococcus mutans and polio virus.
With regard to the intranasal route of vaccination, experiments by Bull and McKee (1929) 
proved that intranasal immunisation of rabbits with killed Streptococcus pneumoniae was 
protective against lethal pneumococcal infection. These workers could not detect serum 
antibody in protected animals. However, Walsh & Cannon, (1938) showed that intranasal 
immunisation resulted primarily in the local production of antibody. Later work by Tomasi and 
others (reviewed by Brandtzaeg, 1984) identified this locally-produced antibody as IgA and that 
most of it was present as secretory IgA (slgA) (Rossen et a!., 1966 a.b).
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1.3.2 TIM structure of slgA
The structure of s lg A  is well-known and well-documented (W aldman & Ganguly, 1974, Tomasi, 
1989). It consists of the familiar arrangement of two light and two heavy chains of the a  isotype 
joined by disulphide bridges. In man it is usually present as a dimer (but can exist as higher 
order polymers, especially in mice), the two IgA molecules held together by a J  ("joining") 
chain. This is a i5 k D a  polypeptide which is also present in pentameric IgM. Dimeric IgA is 
found both in secretions and in serum. However slgA possesses an additional element, an 
80kDa glycoprotein called secretory component (SC).
1.3.3. Processes In the secretion of IgA
The necessary steps in the secretion of IgA at mucosal surfaces represent one of the better- 
understood processes operating in mucosal immunity (reviewed by Brandtzaeg, 1985). 
Secretory component is synthesised by mucosal epithelial cells on the rough endoplasmic 
reticulum as a 95kDa polypeptide. It is core-glycosylated to a M, of l05kDa and is transported 
to the Golgi cistemae. There, complex sugars are added and terminal glycosyiation occurs. The 
glycoprotein is transported to the basolateral cell membrane where phosphorylation of a serine 
residue takes place to give the final 120kDa receptor molecule. J  chain/lgA dimers produced 
by neighbouring plasma cells bind non-covalently to S C  (which serves as an epithelial cell 
membrane receptor for the antibody molecule) and enter the epithelial cell in endocytic 
vesicles. These vesicles transcytose to the luminal membrane, with which they fuse. The 
transmembrane domain of SC is cleaved, releasing mature slgA. At some stage, between the 
initial interaction between SC and IgA and the final secretion from the epithelial cell, two 
disulphide bridges form covalent links between SC and the C m2 domain of one of the a  heavy 
chains.
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1.3.4 Properties of sIg A
The association of polymeric IgA with secretory component endows slgA with certain properties 
which enhance its efficiency. For instance. S C  is thought to reinforce the natural resistance of 
IgA to proteolysis. Clearly this is relevant for antibodies operating in the respiratory and gastro­
intestinal tracts, which are milieux rich in proteolytic enzymes (M cGhee & Mestecky, 1990).
Perhaps a more significant structural feature is the dimerism of slgA, which is reflected in 
several of the biological properties of the molecule. For example, slgA has been shown to be 
highly effective at neutralising viruses (e .g. Taylor & Dimmock, 1985) and its multiple antigen- 
binding sites allow it to agglutinate and inhibit the adsorption of bacteria very effectively. 
Magnusson & StjemstrOm (1982) demonstrated that in this respect slgA is considerably more 
efficient than IgG.
There is much evidence to show that, at least in the gut, slgA inhibits the absorption of 
soluble antigens in an antigen-specific manner (André et al., 1974). This phenomenon is 
termed "immune exclusion". The binding of slgA to antigen does not result in the activation of 
complement. Indeed, it has been shown that IgA can inhibit complement-dependent reactions 
mediated by antibodies of different classes (Russell-Jones et al., 1980, 1981). Thus, by 
combining with antigen and inhibiting its absorption, slgA prevents the antigen being bound by, 
for example, serum IgG, which might result in potentially harmful Immune complexes, such as 
found in IgA-deficient patients (Cunningham-Rundles et a i,  1978). Alternatively, antigen might 
be bound by IgG at the mucosal surface with concomitant activation of complement, leading 
to local inflammation and loss of integrity of the mucosal epithelium, resulting in increased 
absorption of "bystander antigens with the possibility of inappropriate immune responses. Thus 
an important role of slgA is thought to be the down-regulation of other, potentially pathological, 
immune-effector responses to environmental antigens.
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1.3.5 Th e  Initiation of a secretory IgA response
The  main events which are necessary for the initiation of a secretory IgA response at mucosal 
surfaces are reasonably well-understood and have been reviewed recently (M cGhee & 
Mestecky, 1990), but the details, especially those concerning cellular interactions and the 
regulation of the response, remain poorly defined.
Immunocompetent cells can be found in various locations throughout the gastro-intestinal 
and respiratory tracts (G IT  and R T  respectively). In particular, th ey are concentrated in gut- 
associated lymphoid tissue (G A L T) and bronchus-associated lymphoid tissue (B A LT). These 
are defined structures found throughout the length of the G IT  and RT.
Initially, antigen crosses the mucosal epithelium. In the gut this is thought to be mainly via 
the thin dome-shaped layer of epithelial tissue (the follicle-associated epithelium, "FAE") which 
overlies specialised lymph nodes termed Beyer's patches (nam ed after the Swiss scientist 
Johan C onrad Peyer, who first described them in 1677). Although enterocytes are also capable 
of m acro molecular absorption, the mucus layer is thinner above the FA E , thus the microfold 
cells ("M " cells) which constitute the FA E are more accessible to antigen via pinocytosis. 
Furthermore beneath the FA E, within the Payer's patch, is lymphoid tissue rich in B  and T  
lymphocytes, arranged in discrete zones. However, the M cells d o  not express M HC class II 
antigens. Therefore, although they may or may not process antigen, they are presumably 
incapable of presenting antigen to T  helper cells. This function is probably performed by the 
''professional- antigen-presenting cells (A PC), such as macrophages and dendritic cells, which 
are well-represented in Payer's patches. Thus, it is hypothesised that antigen becomes 
associated with MHC class IT** A PC  and is processed and presented to T  helper cells. These 
antigen-stimulated T  cells provide various regulatory signals to B  cells, resulting in B  cell 
differentiation (which commits the B lymphoblasts to being IgA***). Antigen- and cytokine- 
stimulated plasma cell precursors migrate from the lymphoid tissue via the lymphatic system 
and enter the circulation through the thoracic duct. They then target to a variety of secretory 
mucosal tissues where they undergo terminal differentiation into slgA-secreting plasma cells.
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This re-distribution of immunocompetent cells is discussed in greater detail in the next section.
Th e  processes operating in the respiratory tract are not so well-documented. Nevertheless, 
primary stimulation of B cells is also thought to occur in specialised structures, such a s  the 
tonsils and the bronchus-associated lymphoid tissue (BALT). Th e  B A L T exists as aggregates 
of immunocompetent cells and accessory cells. These structures (for which some authors have 
proposed the term ’Bronchus-associated lymphoid units" or BALU; Sminia et al., 1989) are 
analogous to the Payer's patches in the gut. They are randomly distributed along the length 
of the bronchial tree but are often found around bifurcations in the bronchi. Their number 
appears to differ from species to species. In adult rats, for example, between 30 and 5 0  have 
been found to exist (Plesch, 1982). As with Payer's patches, BALU comprise both B and T  cell 
areas. Histochemical studies conducted on rat B A L T  follicles have found this lymphoid cell 
component to consist of -6 0 %  B cells and 40%  T  cells. Of the latter, there are roughly twice 
as many T  cells with the helper phenotype as with the cytotoxic/suppressor phenotype (v a n  der 
Brugge-Gamelkoom & Sminia, 1985). Also present are many non-lymphoid cells: fbroblasts, 
macrophages, interdigitating cells and follicular dendritic cells.
Despite these similarities between BALU and Payer's patches, various important distinctions 
can be drawn between B A L T  and G A LT . For instance, as stated above, T  cells constitute 40%  
of the lymphocytes present in rat B A L T follicles. This contrasts with the situation in rat PeyeFs 
patches, where only 15%  of lymphocytes are T  cells (Jeurissen et al., 1984). Moreover, other 
studies, again conducted on rats, have demonstrated that most of the intraepithelial T  cells in 
the respiratory tract possess the T  helper phenotype (van der Brugge-Gamekoom, 1986). 
Similarly, T  cells in the epithelium lining the human nose are found to be mainly T  helper cells 
(Winther et al.. 1987), whilst in the gut 8 0 %  of intraepithelial T  cells bear the 
cytotoxic/su pressor phenotypic markers (Mow at, 1990). This might be a reflection of the 
generally immunosuppressive processes occuring along the length of the gut, which 
presumably are necessary to maintain oral tolerance. It may well be that, in the light of this 
finding and the presence of the acid barrier in the stomach (together with the digestive 
enzymes in the gut), the respiratory tract represents a more attractive route of inoculation than
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does oral delivery.
Another difference between B A L T and G A L T  concerns the uptake of antigen: whereas 
antigen crosses the intestinal epithelium and enters Foyer's patches via M cells, there are no 
M cells as such in the epithelium lining the respiratory tract. Nevertheless, there are non-ciliated 
epithelial cells which are active in antigen-sampling. In contrast to M cells, which tend to form 
a layer above adjacent lymphocytes, the B A L T epithelial antigen-sampling cells usually extend 
from the bronchial lumen right down to the basement membrane. There is some debate as to 
their relevance. It has been demonstrated that exogenous material can be ingested by the 
entire respiratory tract (Richardson et a/., 1976). In addition, the great majority of antigen In the 
lung is taken up by alveolar macrophages (Hocking & Golde, 1979). However, the local uptake 
of even small amounts of antigen by non-ciliated antigen-sampling cells in B A L T aggregates 
is probably significant because of the intimate association between these cells and infiltrating 
lymphocytes and accessory cells. As with M cells, it is unclear if these specialised epithelial 
cells simply take up and transport antigen or whether they also process and present antigen. 
Certainly they can be induced to express la molecules upon antigen challenge, at least in rats 
(Gregson et at., 1979, Simecka et at., 1986). Interestingly, it has been proven that rat intestinal 
epithelial cells (other than M cells) can also express M H C  class II antigens and present antigen 
to T  cells in vitro, resulting in T  cell proliferation (Bland & Warren, 1986). However, it has not 
yet been shown whether such epithelial cells can present antigen in vivo. Also, it should be 
remembered that la antigen has been found to have a role in intracellular transport systems 
and is not necessarily an indicator of immunological processes (Unanue & Allen, 1986).
1.3.6 Lymphocyte traffic
According to Bjerke and Brandtzaeg (1986), once stimulated by antigen and cytokines most 
B cells immediately migrate from the mucosa-associated lymphoid tissue, via the lymphatic and 
vascular systems, to various secretory tissues such as the gut, respiratory tract, mammary and
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salivary glands. It is thought that various endothelial surface receptors are at least partly 
responsible for the specificity of the homing of these lymphocytes (Streeter et al., 1988). 
Apparently different recognition mechanisms operate in the G A L T  and B A L T  (Brandtzaeg, 
1988), thus it would seem reasonable to assume that different subsets of B  cells, with different 
surface markers, would target with different specificities. That such migration of B cells occurs 
is beyond question. There are numerous examples of local immunisation resulting in secretion 
of antigen-specific IgA at distal mucosal sites (reviewed by Mestecky, 1987). T h e  evidence for 
T  cell migration is less abundant. However, there have been reports indicating that, in mice and 
rats, T  cells traffic in a similar manner to B cells (Guy-Grand et al., 1978, Mattingly & 
Waksman, 1978, respectively).
The  exact molecular basis for the specific targeting of IgA-precursor cells to mucosal 
tissues has not been fully determined although it is clear that there are a number of vascular 
endothelial receptors involved (Streeter et al., 1988). Considerable interest w as generated 
when it was reported that virtually all CD3*'"/CD8*'" intraepithelial lymphocytes (IE L) found in 
the mouse intestine were of the y8 type T  cell receptor (TcR ), (Bonneville et al., 1988, 
Goodman & Lefrangois. 1988), whereas CD3*"/CD8*'* lymphocytes present in non-mucosai 
lymphoid organs and blood far more commonly possess a TcR  of the classical a0 type. 
Naturally it was speculated that this difference in T  cell receptor structure could be the 
molecular basis for specific targeting of IEL to the intestinal epithelium. However, subsequent 
experiments demonstrated the existence of two populations of intestinal IEL in mice (reviewed 
by Viney et al., 1990). One was ys*’* and was thymus-independent in its ontogeny (they could 
be found in athymic mice). The other was a/p*~ and thymus-dependent. Th e  two populations 
were present in roughly equal numbers in normal mice. This discrepancy with earlier results 
is explained at least in part by the finding that in gnotobiotic or very young animals there are 
very few I E L  and those that are present are mostly y 6*~, whilst in older mice there are far 
more IEL of which many more are a/p*1". Thus the ratio of a/p to y 8 cells among the intestinal 
I E L  population depends on the degree of antigen stimulation of the gut and the age of the 
mouse. It would seem therefore, that if the y 5  Tc R  is part of a molecular homing signal it can
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only be operable at an earty stage of development. A  similar degree of uncertainty exists 
concerning the situation in the mouse lung, where estimates of the y5*** T  cell population vary 
from 2 -20 %  (Abraham et al., 1990, and Augustin et al., 1989 respectively).
As stated earlier, the majority of antigens given orally (such as food and inert environmental 
antigens) will result in the suppression of subsequent systemic responses to the same antigen 
given parenterally. This phenomenon is known as "oral tolerance*. It can occur in adults and 
is independent of the mechanisms responsible for the generation of self-tolerance in neonates. 
However, this mechanism does not operate for all antigens to which mucosal surfaces are 
exposed. For instance, replicating antigens such as viruses and bacteria can induce secretory 
and serum antibody responses. Among inert (i.e. non-replicating) antigens, cholera toxin (C T ) 
and its non-toxic, binding B-subunit (C T -B ) have been known for some time to act as potent 
immunogens when fed to rats (Pierce & Gowans, 1975). Subsequently, several studies have 
shown that C T , C T -B  and their analogous E. collcounterparts heat-labile toxin (L T ) and its non­
toxic, binding B-subunit (LT-B ), can generate strong secretory and serum antibody responses 
(Elson & Ealding, 1984a, Chen & Strober, 1990, Clements, 1990, Masked et al., 1987). To  
understand why C T , L T  and their B-subunits act in this way it is necessary to describe their 
structure and properties.
1.4 The properties of C T  and LT
C T  is elaborated by wild-type V. cholerae and is largely, but not exclusively, responsible for the 
symptoms of diarrhoea that can follow infection of humans by V. cholerae (Levine etal., 1984). 
There are many strains of E. coll which can also cause diarrhoea, in both man and animals. 
Among the virulence factors of some of these strains are one or more enterotoxins. The best 
characterised of these are the heat-stable and heat-labile toxins (S T  and L T  respectively). Two 
types of S T  have been identified, S Ta  and S T b  (Burgess etal., 1978). These are both relatively 
small peptides whose relative molecular mass has been determined at between 2kDa and
11
5kDa. Their small size partly explains their heat-stability and also their very poor 
immunogenicity, which has hindered attempts to develop a vaccine. In contrast, L T  is highly 
immunogenic. L T  is very similar, but not identical, to C T  in terms of structure and biological 
activities. L T  consists of one A-subunit of 28kOa, non-covalently linked to five identical B- 
subunit monomers. Each monomer has a M, of -  H .5kD a, thus the L T -B  pentamer is 56kOa 
whilst the L T  holotoxin is 84kDa in size. This is an arrangement very close to that found in C T  
(Gill et a/., 1981). It should be stated that the L T -B  structural genes in LT-producing strains of 
E. coli isolated from different sources exhibit small but consistent sequence differences (Leong 
et a!., 1985). This is reflected in different amino acid compositions. Thus heat-labile toxin B- 
subunit produced by strains isolated from pigs, referred to as pLT-B , differs by 6 amino adds 
from the equivalent protein synthesised by strains isolated from humans (h LT-B ). Two of these 
different amino acid residues are in the leader sequence and so are not represented in the 
mature protein. The other different residues are at positions 4 ,1 3 ,4 6  and 102, as represented 
in the mature protein after cleavage of the signal sequence (Leong et al., 1985). These subtle 
differences between p LT-B  and hLT-B  can be distinguished serologically (Honda et al., 1981 
and Svennerholm & Holmgren, 1986b). Quite why these apparently rigorous strain differences 
exist is puzzling, as the enterotoxin structural genes are plasmid-borne in both pordne and 
human isolates. In addition, these plasmids have been shown to be transmissible (Smith & 
Halls, 1968). It may be that such exchange does occur, but only infrequently, and that simply 
insufficient isolates have been studied.
1.5 The basis of toxicity in C T and LT
As with the structure of the two toxins, their mode of action is very similar. Initially, one of the 
five B-subunit monomers binds to a monosialoganglioside molecule (termed G «,) on the target 
cell membrane (e.g. a mucosal epithelial cell). This primary interaction is sufficient to stabilise 
the toxin molecule on the cell surface and the other monomers rapidly bind other G*,
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molecules with a stoichiometry of 1:1. Once the B-subunit pentamer is fully bound, the toxic A- 
subunit can enter the cell. The exact mechanism by which this is achieved is unclear. The 
secondary structure of the A-subunit is far less ordered than the that of the B-subunit (Surewicz 
et a/., 1990) and so might conceivably pass across the cell membrane in a partially unfolded 
state, with the B-subunit playing no further role. Such a model was proposed by Gill (as 
described by Stephen & Pietrowski, 1986). However, the results of some in vitro experiments 
on tissue culture cells suggest that both A - and B-subunits enter the cell in endocytic vesicles. 
Of course, these findings might be irrelevant to the situation in vivo. Whatever the debate over 
the method of entry into the cytoplasm, it is widely agreed that the target for the A-subunit, 
which causes the toxicity, is a regulatory "G" (guanidine-binding) protein, part of the stimulatory 
complex associated with membrane-bound adenylate cyclase. This stimulatory complex is part 
of the cell's physiological apparatus for increasing intracellular cyclic adenosine monophosphate 
(cAM P) levels in response to various signals (e.g. hormones). The A-subunit is cleaved, 
yielding A, (23kDa) and A j (5kDa) fragments. Binding of the A, fragment to the activated form 
of this G  protein, (termed G„S), prevents hydrolysis to the inactivated state. As a result, the 
stimulatory complex cannot be inhibited and adenylate cyclase is irreversibly activated, leading 
to high levels of cAMP. The next steps are not well-defined but it is clear that these high 
intracellular cAM P levels have a multitude of effects. One of these is thought to be the 
phosphorylation by cAMP-dependent kinases of membrane proteins which act as ion channels, 
resulting in de-regulation of ion-exchange and secretion in enterocytes, the clinical effect of 
which is severe diarrhoea.
1.6 The immunogenicity of C T  and L T
In many ways C T  is an extremely well-characterised molecule. However, there is one area 
which remains poorly-defined: the molecular basis of the mucosal immunogenicity of C T  and 
LT.
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Historically, C T  was a good choice ot antigen to study, being available in a  highly purified form 
in relatively large amounts. Furthermore, a model already existed for testing the protective 
effects of anti toxin antibody (the ligated rabbit ileal loop model). The  probable requirement for 
C T  antigens in any effective human oral cholera vaccine underlined the significance of such 
research.
Earty studies demonstrated that cholera toxoid was capable of provoking a response after 
intraperitoneal priming and oral boosting (Pierce & Gowans, 1975) and that native C T  had 
interesting immunomodulatory properties in vivo (Kateley et at., 1975). These latter workers 
showed that i.v. inoculation of small doses of C T  (down to 0.1 pg) could, depending on the time 
of administration relative to immunisation, enhance or suppress the mouse serum antibody 
response to sheep red blood cells (SRBC). The authors suggested that these effects were due 
to increased cAM P levels in lymphocytes resulting from adenylate cyclase activation or that the 
cytotoxic nature of C T  released mitogenic macromolecules from dead cells. This work 
supplemented an earlier brief report (Northrup & Fauci, 1972) that C T  could have an adjuvant 
effect on the mouse response to S R B C  and that this adjuvanticity was destroyed by heating 
C T  prior to inoculation. Pierce (1978), in experiments with C T , C T -B  and cholera toxoid 
established that efficient oral priming of rats could only occur if the antigen was in a form which 
could bind to G m,. Thus either holotoxin or C T -B  could stimulate vigorous local responses after 
feeding but cholera toxoid had no such effect, despite retaining its immunogenicity when given 
parenterally. Furthermore, this work demonstrated that the holotoxin was about ten times more 
immunogenic (by molar ratio) than the B-subunit alone. Presumably this was a reflection of the 
adenylate cyclase activation brought about by the toxic A-subunit. Th e  third important finding 
of this research was that local immunologic memory could persist for 8 months after oral 
priming.
This line of research was continued by Elson and Ealding (1984a,b). They compared the 
local and systemic responses of mice fed C T  o r Keyhole Limpet haemocyanin (KLH), a protein 
which is highly immunogenic when given intravenously. They showed that feeding 5mg of KLH 
did not induce any antigen-specific intestinal antibody and caused only a small increase in
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similar serum  antibody litres. In contrast, 10pg of C T  was sufficient to induce CT-spedfic slgA 
and high anti-C T serum levels of both IgA and IgG isotypes. This correlated with the detection 
of helper T  cell activity in mucosal (Peyer’s patches, mesenteric lymph nodes) and systemic 
(spleen) lymphoid tissue. More significantly they found that if C T  was co-fed with KLH, a KLH- 
specific s lgA  response could be induced, together with greatly enhanced serum anti-KLH titres. 
That is, co-administration of C T  could overcome oral tolerance to an unrelated antigen. This 
phenomenon has become known as "mucosal adjuvantictty".
Th u s  the evidence that C T  has a strong adjuvant effect on the mucosal reponses to 
unrelated and physically unconnected antigens is very strong. Equally, there is good evidence 
that C T  a nd the other antigen must be given by the same route and approximately at the same 
time (Lycke & Holmgren, 1986). It is less clear if C T -B  also has this property. There are some 
unequivocal reports (Tamura et a!., 1989), which established that anti-viral serum titres were 
higher in mice which received an influenza virus haemagglutinin (H A) vaccine intranasally in 
conjunction with C T -B  than in mice which received vaccine alone. They also demonstrated far 
higher nasal slgA concentrations in these mice, but did not prove its spedficty. The  question 
of whether C T -B  can act as a mucosal adjuvant is of some importance. The answer has 
obvious implications for the design of subunit vaccines aimed at stimulating mucosal responses 
and m ay reveal an insight into the molecular mechanism of the mucosal adjuvanticity of C T. 
For example, is adenylate cyclase-activating activity essential? This was thought to be the case 
initially. However, it became obvious that C T -B  did behave in a manner qualitatively similar to 
C T  in vivo, in that it can stimulate both secretory and serum responses after oral inoculation 
and does not induce oral tolerance (Pierce, 1978, Elson & Ealding, 1984a,b). Further in vitro 
studies showed that C T -B  shared other properties with the holotoxin. Woogen and his co­
workers (Woogen et al., 1987) were able to prove that C T -B , whilst not as efficient as C T, 
behaved similarly in that either molecule could inhibit mitogen- or antigen-induced T  cell 
proliferation or anti-IgM-mediated B  cell proliferation. This suppressive effect could be abolished 
if the toxin or B-subunit was pre-incubated with G U1. One distinction which the authors did note 
was that only C T  could inhibit LPS-driven B cell proliferation. They concluded that the binding
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of C T  or C T -B  to the lymphocyte cell surface could inhibit the activation mechanism leading to 
proliferation and, in addition, a further mechanism involving adenylate cydase activation could 
also have a suppressive effect.
The  report by De Aizpurua and Russell-Jones (1988), in their review of mucosal 
immunogens, established that several substances could elicit systemic responses after oral 
inoculation. These included E . co liadhesins (the pili K99 and 987P from animal E T E C  strains), 
influenza vaccine (containing haemagglutinating activity) and numerous lectins, such as 
Pokeweed mitogen (PWM) and concanavalin A  (con A). Furthermore, these authors showed 
that if the K99 pili or L T -B  were fed to mice in conjunction with various sugars, known to be 
responsible for the receptor-binding activity of the immunogens, then the serum responses to 
these molecules could be effectively abolished (mirroring the results in  vitro, using C T -B  mixed 
with G M1-containing liposomes, obtained by Woogen et at, 1987).
When all these findings are viewed in conjunction, it would seem that at least part of the 
mechanism of mucosal immunogenicity of C T  rests on its ability to bind G y „  and so this 
property is shared by C T -B  and L T -B . One explanation put forward which combines the known 
data into a coherent model, is that binding to receptor molecules on the surface of enterocytes 
by-passes the normal antigen-sampling procedure occurring in Peyer's patches, which is that 
process responsible for maintaining oral tolerance. Blocking of the binding sites on the mucosal 
immunogens (by sugars or whole gangltoside molecules) forces the molecules to be processed 
via Peyer's patches and so results in unresponsiveness (De Aizpurua & Russell-Jones, 1988).
It is difficult to determine the significance of studies in vitro on the effects of C T  and C T -B  
on T  and B cells (Woogen et a/., 1987, Elson & Solomon, 1990, Anastassiou et ai„ 1990, 
Dugas etal., 1991) to the immunogenic mechanism in vivo. O n  the basis of his own published 
findings Elson appears to suggest that native C T  or C T -B  can bind to the surface of T  cells, 
which inhibits T  cell proliferation and that in some way T  suppressor cells (presumably involved 
in the maintenance of oral tolerance) are inhibited preferentially over T  helper cells, the end 
result being an anti-CT or a n ti-C T-B  response. A  number of factors make it difficult to ascertain 
what might occur in vivo-, the far greater surface area of ileal enterocytes would suggest that
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they could adsorb considerably more antigen (via receptor-mediated endocytosis) than the M 
cells of the FAE. However, there is a much higher concentration of immunocompetent cells in 
G A L T , in a microenvironment which is probably very  different to that experienced by IE L  or 
lymphocytes in the lamina propria. Secondly, as stated earlier, there is evidence for the 
presentation of antigen by enterocytes in vitro, but no evidence if this occurs or not in vivo. 
Finally, Elson found in vitro that only native C T  or C T -B  exerted inhibitory effects on T  cells. 
However, it is conceivable that enterocytes or other cell-types might process such antigens 
before they are encountered by lymphocytes.
The  mechanism of mucosal immunogenicity outlined by De Aizpurua and Russell-Jones 
(1988) is not necessarily inconsistent with the published research (Guyon-Gruaz et a i,  1986) 
claiming to obtain serum anti-CT antibody after oral immunisation of mice with synthetic 
peptides corresponding to either amino acids 30-50 o r 50-75 of the C T -B  sequence. The  30-50 
peptide contains the Arg-35 residue reputed to be involved in receptor-binding, thus this peptide 
may have retained some affinity for G y,. The authors do not present any data on this point. 
Oral immunisation with the other peptide required four inoculations to elicit a serum response, 
despite the authors having selected the peptide for its putative immunogenicity.
1.7 Chemical conjugation and genetic fusion of antigens with C T -B  and LT-B
1.7.1 CT-B/antlgen conjugates and fusion proteins
In the light of the considerable body of evidence suggesting that C T -B  (and probably therefore 
L T -B ) possess at least some of the intrinsic mucosal immunogenicity of the holotoxin, it is not 
surprising that several attempts have been made to utilise this property so as to enhance the 
mucosal response to unrelated antigens.
The feasibility of this technique was demonstrated by the coupling of horseradish 
peroxidase (H RP) to C T -B , using glutaraldehyde (McKenzie & Halsey, 1984). The  resulting
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conjugate was shown to retain some Gy,-binding capability. 50pg of C T -B  coupled to 30-90pg 
of H R P was used to inoculate mice intraduodenally. The serum and secretory anti-HRP 
responses of these mice were compared to those of mice immunised with a  non-conjugated 
mixture of C T -B  and HRP, or H R P alone. The authors found that chemical linkage of HRP to 
C T -B  was necessary to obtain optimal slgA and serum IgG anti-HRP titres.
A  similar approach was employed (Bessen & Fischetti, 1988,1990) in an attempt to protect 
mice against colonisation by group A  streptococci. Synthetic peptides, corresponding to 
conserved sequences of streptococcal M protein, were covalently linked to C T -B  and used to 
inoculate mice intranasally. It was shown that, despite immunised animals mounting only a poor 
salivary IgA response, such a procedure could protect mice against pharyngeal colonisation 
after intranasal challenge by live streptococci.
Again, covalent coupling of C T -B  to an antigen, namely S. mutans surface protein antigen 
l/ll (Ag l/ll), was used to elicit mucosal and systemic responses in orally inoculated mice, as 
judged by the presence of Ag l/ll-specific antibody-secreting cells in salivary glands, mesenteric 
lymph nodes and spleen and by the presence of specific serum antibody (Czerkinsky et al., 
1989).
The  findings of McKenzie and Halsey (1984), concerning the need for C T -B  to be covalently 
coupled to the antigen of interest, are in direct contrast with the results obtained by Tamura 
and his co-workers (Tamura et al., 1988,1989), who experimented with the enhancement, by 
C T -B , of the antibody response to an intranasaliy inoculated influenza virus vaccine. In common 
with many other reports on the subject, they found that C T -B  was less efficient than the 
holotoxin at enhancing responses. However, they also discovered that, in their model, C T -B  
could act as a mucosal adjuvant simply by being mixed with the vaccine. T h e  C T -B  used in this 
study was supplied by Sigma Chemical Company and was not contaminated with A-subunit as 
determined by S D S -P A G E. It may well be that the respiratory and intestinal immune systems 
react differently to C T -B , otherwise it is difficult to reconcile the data of the two research 
groups. Alternatively, it may be significant that different antigens were studied.
A  more sophisticated technique than chemical conjugation is to create genetic fusions,
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consisting of C T -B  or L T -B  structural genes linked to the sequence encoding the antigen of 
interest. This has been achieved independently by several researchers (Guzman-Verduzco & 
Kupersztoch, 1987, SchOdel & Will, 1989, Dertzbaugh & Macrina, 1989 and Clements. 1990). 
Such an approach has several advantages over chemical coupling. Genetic fusions are much 
more versatile; antigens or short peptide fragments defining epitopes of any desired sequence 
can, in theory, be fused to the carboxy or amino termini of the carrier molecule. The products 
of such fusions would also have a precisely defined composition, which would be consistent 
from batch to batch. In addition, chimeric proteins could, if desired, be delivered by live oral 
vaccines (SchOdel etal., 1990a,b).
Dertzbaugh et al., (1990) have reporied the construction of a vector which expresses 
residues 345-359 of the glucosyltransferase B (gtf B) from S. mutans as a fusion with the 
amino terminal of C T-B . Both moieties of this fusion protein retained their antigenicity (as 
determined by immunoblotting) and, more importantly, their immunogenicity, eliciting gut IgA 
and serum IgG responses when fed to mice.
1.7.2 LT-B/arrtlgen fusion proteins
One of the earliest fusion plasmids reported was constructed by Guzman-Verduzco & 
Kupersztoch (1987). They successfully fused a sequence encoding E. coU S T  to the 5' end of 
the L T -B  structural gene. The  L T -B  moiety retained antigenicity in vitro in ELISA and Western 
blot analyses. Unfortunately, the S T  moiety retained toxicity, causing fluid accumulation in the 
suckling mouse model (Gianella, 1976). The immunogenicity and possible pentamerisation of 
the chimaera were not investigated. S T  was an attractive choice of antigen to couple to LT-B. 
being poorly immunogenic by itself. Any molecular combination which could elicit S T - and L T - 
neutralising antibodies in the gut raised the possibilty of producing a single vaccine to protect 
against enterotoxigenic E. co/Amediated diarrhoeal disease.
Another ST/LT-B gene fusion was made by Clements (1990), in which a synthetic
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oligonucleotide corresponding to part of the S T  gene, was joined to the 3' terminal of the LT-B  
structural gene. This approach avoided the need to eliminate the leader peptidase recognition 
site at the amino terminal of LT-B, which is necessary in fusions to the 5' terminal of the LT-B  
coding sequence, to prevent cleavage of fused epitopes along with the L T -B  leader peptide. 
Clements investigated the hybrid protein and found that the S T  toxicity was effectively 
abolished, whilst mice immunised intraperitoneally with crude or purified peparations of the 
molecule could generate S T - or LT-B-specHic serum antibody. However, whether such a fusion 
protein could elicit a response when given orally is doubtful; the author presented data implying 
no multimer-formation or Gy,-binding occurred.
Another plasmid vector had been described previously (SchOdel & Will, 1989). This 
contained a  polylinker region at the 3' end of the L T -B  gene. A  number of sequences encoding 
surface (sAg) or core (cAg) antigens from human (H BV) or Woodchuck (W H V ) hepatitis B 
viruses were inserted into this vector, creating several chimaeric proteins. The  authors 
established that the antigenicity of both moieties in the fusion protein was retained. However, 
no data were presented on multimer-formation or Gy,-binding, so it is unclear if these important 
attributes were also retained by the hybrid molecules. When mice were fed iive attenuated 
strains of Salmonella dublln expressing these fusion proteins, they developed LT-B-specific 
serum antibody after priming, the titres of which could be boosted by a second oral inoculation. 
However, no virus-specific serum antibody was detected in these animals.
Subsequently the same group constructed a plasmid (pFS20) in which two over-lapping T  
cell epitopes of HBVcAg (amino acid residues 120-140) and a B cell epitope from HBVsAg 
(amino acid residues 133-140) were expressed in a single fusion protein with L T -B  (SchOdel 
et al., 1990a). W hen mice were fed live attenuated S. dublln producing this polypeptide they 
developed serum anti-LT-B. In addition, mice of the H-2b haplotype (C57BI/10) generated 
splenic T  cells which proliferated In vitro in the presence of a  synthetic peptide corresponding 
to residues 121-145 of HBVcAg. However, neither these mice, nor Balb/c mice (H-2*), 
developed serum antibody against the B cell epitope. Interestingly, essentially the same peptide 
(133-143), when fused to the carboxy terminal of HBVcAg, was able to generate serum
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antibody when presented to mice by attenuated bacteria, using the same strain, dose and route 
of inoculation (Schôdel et al., 1990b).
It is clear from the published data that attempts at immunisation using L T -B  fusion proteins 
are very promising, although initial experiments have had mixed success. However, the ability 
of these fusion proteins to form pentamers (which appears to be essential for binding to G*,) 
is, where reported, often shown to be diminished or totally abolished. If current theories on 
mucosal immunogenicity are correct, this could substantially reduce their efficacy.
The  aim of this project was to investigate methods of improving the immunogenicity of peptide 
antigens inoculated via mucosal surfaces. T o  this end, a plasmid vector was constructed which 
would allow the in-frame insertion of peptides at the 3' terminal of the L T -B  structural gene, in 
such a way that the resulting fusion proteins retained the ability to pentamerise and bind to G,,,.
Additionally, having constructed such a fusion vector, it was intended to insert appropriate 
peptides and to confirm the identity of the fusion plasmids by DNA sequence determination. 
The  resultant chimaeric polypeptides were to be characterised in vitro using S D S- 
polyacrylamide gel (S D S -P A G E ), immunoblotting and G M1-linked ELISA analyses.
Finally, the immunogenicity of these fusion proteins in mice was to be investigated, both 
as partially-purified protein and by expression in a suitable live attenuated bacterial host.
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C H A P T E R  2
Materials and Methods
2.1 Bacterial strains
A number of strains were employed in this project. These are detailed in Table 2.1.
Table 2.1 The bacterial strains employed In this study
Organism Strain Relevant phenotype Reference
E. coli HB101 K12/B hybrid Bolivar & Backman, 1979
E. coli TG1 F Carter et al., 1985
S. typhimurium LB5010 r‘m+ Masked et al., 1987
S. typhimurium SL1344 aroA '  aroD ' Dougan et al., 1988
B. pertussis CN2992 Smr Roberts et al., 1990
2.2 Media for bacterial growth
Luria broth (L-broth), Luria agar (L-agar), top agar and Cohen & Wheeler agar (C W  agar) were 
all prepared by the media production unit at Wellcome Research Laboratories using standard
formulae.
L-broth
1.0% w/v tryptone 
0.5%  w/v NaCI 
0 .5%  w/v yeast extract
L-agar was as above, solidified with 1.5% Bacto agar. Minimal medium was made in the 
laboratory according to the formula below:
1.5% w/v agar 
0 .6%  w/v Na*HP04 
0 .3%  w/v K H jP O ,
0.1%  w/v NH4CI
in distilled water, adjusted to pH7.4 and autoclaved. 1M MgSO«, 20%  (w/v) glucose, 0 .1%  (w/v) 
thiamine and 1M CaCL, were prepared and sterilised separately. 200pJ, 1ml, 1ml and I0pl 
respectively of these solutions were added to 100ml of the molten agar prior to pouring the 
plates.
2.2.1 Media supplements
Where appropriate, media were supplemented with antibiotics according to Table 2.2.1. Stock 
solutions of antibiotics were prepared in distilled water, sterilised by passage through a 0.22pm 
filter (Millipore, UK) and stored in aliquots at -20°C. C W  blood agar plates contained 10% 
defibrinated horse blood (Tissue Culture Services Limited, UK).
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Table 2.2.1 Antibiotics used to supplement culture media
Antibiotic Stock solution Working concentration
ampictllin 200mg/ml 100pg/ml
streptomycin 20mg/ml 100ug/ml
2.3 Culture conditions
E. coli and S. typhimurium were routinely cultured at 37°C on L-agar plates or in L-broth. E. coll 
TG 1  was maintained on minimal medium plus thiamine. B. pertussis was grown on C W  blood 
agar plates at 35°C. Stock cultures of all strains were stored in aliquots in liquid nitrogen.
2.4 Plasmids
Plasmid pBRD026, the starting-point for the constructions described in this thesis, was made 
by Maskell et al., (1987), by sub-doning a 600 base-pair £coR1 fragment (carrying the porcine 
L T -B  subunit cistron) from pEW D299 (Dallas et al., 1979) into the EooR1 site of pBR322. The 
resulting plasmid (pBRD026) expresses L T -B  constitutively from the P1 ("anti-tet") promoter.
Th e  fusion vector, pFV 1 , was made by the insertion of specially-designed linker 
oligonucleotides at the 3' terminus of the L T -B  structural gene. L T -B  fusion constructs were 
created by the further addition of oligonucleotides at unique sites within the linker sequence, 
as described in section 3.4.
24
2.5 DNA manipulations
2.5.1 Agarose gel electrophoresis of DNA
D N A in gel loading buffer w as subjected to preparative and analytical electrophoresis in 
horizontal gels consisting of 0 .8 %  (w/v) agarose in Tris/borate/EDTA (TB E ) buffer containing 
0.5pg/ml ethidium bromide.
5» oel loading butler 
30%  v/v glycerol 
0.25% w/v bromophenol blue 
50mM Tris in distilled water
TB E  buffer 
1.08% w/v Tris 
0.55% w/v boric acid 
0.1%  w/v E D T A  in distillled water
2.5.2 Phenol extraction and ethanol precipitation of DNA
D N A in aqueous solution was treated with an equal volume of Tris-buffered phenol/chloroform, 
to remove proteinaceous impurities, then with an equal volume of chloroform, to remove 
residual phenol. DNA was precipitated from aqueous solution by the addition of sodium acetate 
(pH4.5) to a concentration of 0.3M and the addition of 2.5 volumes of pre-cooled absolute 
ethanol. The mixture was held at -20°C for 10 minutes and the precipitated DNA pelleted by 
centrifugation in a bench centrifuge for 5-10 minutes. Salt was removed by washing the pellet 
in cold 70% ethanol. The  pellet was spun again for 2-3 minutes and the supernatant poured 
off. The DNA was dried under vacuum in an Unisdence "univap” concentrator. Once dry, the
25
pellet was dissolved in an appropriate volume of sterile distilled water and stored at -20°C.
Tris-buffered phenoVchloroform 
100ml phenol 
96ml chloroform 
4ml isoamyl alcohol
(phenol supplied by BRL Gibco, Gaitesburg, Maryland, U S A , rest supplied by BDH, UK), 
equilibrated with 10mM Tris -H C I pH8.0
2.5.3 Gel purification of DNA
DNA was subjected to electrophoresis as described in 2.5.1. Fragments of interest were 
excised from the gel and purified according to the "freeze-squeeze" technique of Tautz & Renz 
(1983). The gel slice was immersed in 1mlof buffer (0.3M sodium acetate, im M  E D T A  pH7.0) 
for 30 minutes in the dark at room temperature. The  gel piece was dried on Whatman 3mm 
paper, transferred to a fresh eppendorf tube and frozen in a dry ice/ethanol bath for 20 
minutes. The  gel slice was then transferred to a Spin-X column (Costar, Massachusetts, USA) 
and spun for 10 minutes in a  bench centrifuge. The gel matrix was retained by the filter in the 
column (a low-binding 0.22pm  cellulose acetate membrane). The D N A passed through in 
solution and was purified according to the method detailed above (2.5.2).
2.5.4 Synthesis of oligonucleotides
Generally, synthetic oligonucleotides were prepared by Hugh Spence and Martin Carrier at 
Wellcome Research Laboratories using a Milligen 7500 D N A synthesizer (Millipore, UK ). The
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resulting oligonucleotides were purified by high pressure liquid chromatography (H P LC ) and 
lyophilised. About 1 O . D ^ , ^  unit of the oligonucleotides was dissolved in 200pi of sterile 
distilled water. 100pl of this was diluted with a  further 400pl of distilled water and the 
absorbance at 260nm, relative to a blank of water alone, was determined using quartz cuvettes 
and an LKB Ultrospec II spectrophotometer. (O ne O .D . j* ^  unit of an oligonucleotide w as taken 
to coontain approximately 40pg). The O . D ^ ^  w a s  also determined to detect contamination, 
which was found to be neglible.
About 10picomoles of each oligonucleotide were treated with 0.5-1.0 units of T4  
polynucleotide kinase (Boehringer Mannheim), u sed  according to the suppliers instructions, in 
1x kinase buffer. Complementary oligonucleotides were then mixed in an eppendorf tube, 
boiled for 5 minutes and the tube left in the water bath which slowly cooled to room 
temperature, allowing the oligonucleotides to anneal.
1Qx kina§9  tgytfgr 
0.5M Tr is -H C I pH7.6 
0.1 M M gCI,
50mM dithiothreitol 
im M  E D TA
2.5.5 Ligations
2.5.5.1 Preparation of vector DNA
Plasmid D N A for use in ligations with oligonucleotides was incubated with the appropriate 
restriction endonuclease(s) together with calf intestine alkaline phosphatase (Boehringer) at a 
concentration of 1 unit/pg DNA/hour. The reaction products were separated by agarose gel 
electrophoresis as outlined earlier. The desired band  was purified as described in 2.5.3. and
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resuspended in 20pl of sterile distilled water. A small sample (~2pl) was run on an agarose 
gel to quantify the DNA concentration in the preparation.
2.5.5.2 Ligation reactions
20-50ng of prepared vector was used per ligation with a series of dilutions of oligonucleotides 
(ranging from neat to 1/10,000). "Sticky-end" ligations were carried out at 15°C overnight in a 
total volume of 20pJ, including 2pl of T4  DNA ligase (Gibco, BRL) and 4pl of 5x ligase buffer 
(from the same supplier) together with 1pJ of 10mM A TP , (the rest of the reaction volume 
consisting of vector preparation and sterile distilled water). A control reaction (with prepared 
vector but no oligonucleotides) was also performed. Ligation reaction products were used to 
transform bacteria as described below.
2.5.6 Transformation of bacteria
2.5.6.1 Preparation of competent E.coll
E. coh was transformed according to the method of Cohen et al., (1972) as described by 
Sambrook et al., (1989). Competent cells were prepared by diluting an overnight culture 1/100 
in fresh L-broth and growing at 37°C in an orbital shaker until an O .D ^ n m  of 0.4 was attained. 
The cells were harvested by centrifugaton (~3,000g for 5 minutes), washed once in ice-cold 
50mM C aClj and resuspended in half the original culture volume in cold C a C I, and left on ice 
for 1 hour. The cells were then harvested as before and resuspended in 1/25 of the original 
culture volume.
2.5.6.2 Transformation conditions
20-50ng of DNA in a volume of 10pl was added to 200pl aliquots of competent cells in
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eppendorf tubes. These were left on Ice for 1 hour. Control experiments were performed in 
which aliquots of competent cells were treated with a known amount (-2 5 ng) of plasmid DNA 
(e.g. pBR322, p U C l8 ) or received no DNA at all. The suspensions were heat-shocked in a 
42°C water-bath for 2 minutes and then put back on ice momentarily. 1 ml of L-broth was added 
to each tube and the cells were allowed to grow for 90 minutes at 37°C. 100pl of each sample 
was spread over L-agar plates containing appropriate selective antibiotics and incubated at 
37°C overnight.
2.5.6.3 Transformation of S. typhlmurlum LB5010
Competent cells of LB5010 were prepared using essentially the same technique as that for 
HB101. However, after harvesting the culture, the cells were initially resuspended in 1/2 the 
original culture volume in ice-cold 0.1M MgCI2 and left for 30 minutes on ice. Next, the cells 
were harvested in 1/2 the original culture volume in cold 0.1 M C aClj and left for a further 30 
minutes in ice. After this step the cells were suspended in 1/25 the original culture volume in 
cold 0.1 M CaCL, and the procedure was the same as that for the transformation of E. coU.
2.5.7 Transduction of Salmonella strains
2.5.7.1 Preparation of high-tit re lysates
Smooth vaccine strains of Salmonella are difficult to transform by conventional methods; 
however they can readily acquire foreign D NA by transduction with the generalised transducing 
phage P22. LB5010 was transformed with plasmids of interest as detailed in 2.5.6.3. Cultures 
with the transformed phenotype were grown overnight at 37°C. Duplicate 200pl aliquots of 
these cultures were infected with different dilutions (10‘2. 10*. 10*, and 10*) of a stock
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suspension of P22. These were incubated statically at 37°C for 1 hour and then mixed with 3ml 
of molten top agar and spread onto L-am p plates. Once set these plates were incubated at 
37°C for approximately 7hrs, by which time confluent plaques were apparent on some plates. 
3ml of T2  bufffer were then added to those plates exhibiting near confluent lysis. The plates 
were left to soak overnight at 4*0. Th e  top agar was then scraped off and vortexed vigorously 
with the T2  buffer. The agar was removed by centrifugation for 15 minutes at 27,000g and a 
few drops of chloroform added to kill the remaining cells in the lysate. Any surviving cells were 
removed by passage through a 0 .22p m  filter.
T2  buffer 
70mM NaCI 
30mM K*S04 
15mM N ajH P04 
10mM KHjPO«
0.5mM M gS 04 
0.05mM Caclj 
0 .1 %  w/v gelatin
2.5.7.2 Transduction of S. typhlm urlum  SL1344
200pl aliquots of a stationary phase overnight culture of SL1344 aroA '  aroD  '  were infected 
with different volumes (0-40pl) of the previously prepared P22 lysate. The aliquots were left at 
37°C for 1 hour for the phage to adsorb to the bacteria. After this incubation lOOpI of each 
aliquot was spread onto L-amp plates supplemented with 5mM E G TA  (which purges the phage 
from the culture by preventing viral readsorption) and incubated overnight at 37°C to give rise 
to colonies with the expected transduced phenotype.
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2.5.8 Small scale preparation of plasmid DNA from E. coll
Small scale preparations ("minipreps") of plasmid DNA were obtained using a modification of 
the Bimboim & Doty (1979) alkaline lysis method as described by Sambrook et ai, (1989). 
Colonies with the desired phenotype were picked into 3ml of L-broth containing selective 
antibiotics and grown overnight at 37°C in an orbital shaker. 1.5ml of this culture was 
transferred to an eppendorf tube and the cells pelleted by centrifugation for 2 minutes in a 
bench centrifuge. The supernatant was removed and the remainder of the culture was added 
to the tube. These cells were pelleted as before and the supernatant removed. The  pellet was 
dried and resuspended, with vigorous vortexing, in 100pJ of solution 1 and left at room 
temperature for 5 minutes. 200pl of solution 2 was added and the mixture incubated on ice for 
5  minutes. 150pl of solution 3 was added and, following a further 5 minute incubation on ice, 
the suspension was spun for 5 minutes in a bench centrifuge. 400pl of the cleared supernatant 
was transferred to a fresh eppendorf tube containing 1 ml of cold absolute ethanol. The mixture 
was held at -20°C for 10-20 minutes and the precipitated DNA was collected by spinning for 
5 minutes in a bench centrifuge. Th e  DNA pellet was dried, resuspended in 400pl of solution 
4 and purified as outlined earlier. RNA in the samples was removed by digestion with 20pg/ml 
RNase A for 30 minutes at 37°C.
Solution 1 
0.1 M ED TA  
30mM Tris-HCI
Solution 2 
1 %  w/v SDS 
0.2M NaOH
Solution 3 
3m NaOAc pH4.8
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Solution 4 
0.1M NaOAc 
50mM Tris-HCI pH8.0
2.5.9 Large scale preparation of plasmid DNA from E. coll
Large scale preparations of plasmid DNA were performed using essentially the same method 
as above, scaled up 100 fold, except that prior to phenol/chloroform extraction samples were 
treated with 1mg/ml proteinase K (Boehringer) for 1 hour at 56°C.
2.5.10 Transformation of E. coll with M13 DNA
DNA sequences of interest were sub-cloned into the replicative form of M13 vector mp19 
(Messing & Vieira, 1982), obtained from Pharmacia (Sweden). Competent TG1 cells were 
prepared as described previously. These were transformed with 10pl of M13 ligation mixtures 
and then added to 3ml aliquots of molten top agar containing 200pJ of late log phase TG1 
seeding culture, 50pl of 20mg/ml X-gal solution and 10pl of 0.1 M IPTG . This mixture was 
poured over an L-agar plate and incubated at 37°C overnight. Recombinant M13 plaques were 
colourless whilst wild-type plaques were blue.
X-oal solution
20mg/ml 5-bromo-4-chloro-3-indolyl p-D-galactoside 
in dimethyl formamide, stored at -20°C
IP TQ  y?'UlK>n
0.1 M isopropyl p-D-thiogalactopyranoside 
in distilled water, stored at -20°C
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2.5.11 Preparation of single stranded DNA from M13 plaques
Recombinant M13 plaques were picked into 2ml of 1/100 dilutions of E. coU TG1 overnight 
cultures. These were grown for 6 hours at 37°C in an orbital shaker. Bacterial cells were then 
pelleted in a bench centrifuge. 1 ml of the supernatant was transferred to a fresh eppendorf tube 
and the phage precipitated by the addition of 200pl of 20%  polyethylene glycol (P E G  6000) in 
2.5M NaCI. Purified single stranded DNA was obtained from the pelleted phage by 
phenol/chloroform extraction etc. as detailed in 2.5.2.
2.5.12. DNA sequence determination
DNA sequence determination from single stranded DNA templates was achieved using a 
modification of the dideoxy chain termination method (Sanger et a/., 1979); that of Tabor and 
Richardson (1988) employing altered T7  polymerase. Chain elongation was initiated with 
custom-made oligonucleotide primers, complementary to a region 50bp upstream (S') of the 
L T -B  stop codon. Sequencing reactions were executed with reagents from the "Sequenase" 
version 2.0 kit (United States Biochemical Corporation, Cleveland, Ohio, USA) and with 
o -^ S -d A TP  from Amersham International (Amersham, Bucks, UK).
The  reaction products were heated to 95°C for 5 minutes just prior to loading onto 
pre-heated 6 %  (w/v) acrylamide/7M urea wedge gels. These were run at 60 watts constant 
power for -2  hours, fixed in 10% methanol/10 %  acetic acid in water for 45-60 minutes, dried 
under vacuum and put up for autoradiography with Kodak X-Omat S  100 film. Autoradiographs 
were developed with a Fuji RGII automatic x-ray film processor.
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2.6 Analysis of E . c o ll  periplasmlc fractions
2.6.1 Preparation of periplasm lc fractions of £ . coll
Periplasmic fractions were obtained from E. coU cultures as described by Hirst et at., (1984a). 
Briefly, cultures were grown in L-broth to late log phase ( O .D . ^ ^  -1 .0 ). Cells were collected 
by centrifugation and washed once in ice-cold PBS. The cell pellet was then resuspended in 
1/25 of the original culture volume in 0.3M sucrose buffered with 0.1 M phosphate to pH7.6. 
Ethylene diamine tetra-acetic acid (E D TA ) and lysozyme were added to a final concentration 
of 5mM and 20pg/ml respectively. The suspensions were left on ice for 20-25 minutes with 
occasional agitation and then centrifuged at 20,000g for 15 minutes to pellet the sphaeroplasts. 
Th e  supernatant containing the periplasmic proteins was stored at -20°C.
2.6.2 6-Galactosldase and 6-Lactamase assays
These assays were performed upon the periplasmic and cellular fractions obtained by the 
above procedure. T o  assay B-gaiactosidase. lOOpi of a soluble periplasmic fraction or a cell 
sonicate (obtained by sonicating cell pellets in 1 ml of sphaeroplasting buffer on ice for 1 
minute, in 10 second pulses, using a standard M S E sonicator and probe) were added to 900pl 
of reaction buffer and mixed by vigorous vortexing with 20pJ of toluene. The  samples were 
incubated at 37°C for 40 minutes with occasional vortexing. Th e  reaction was started by the 
addition of 200pl of O P N G  solution and was allowed to proceed for varying times (30 seconds 
to 2 minutes) before quenching with 500pl of 1M Na2C O a. Th e  absorbance at 420nm of the 
samples was read using an LKBII ultrospec spectrophotometer. A  graph of absorbance against 
time was drawn and the gradient determined to give the initial reaction rates for the periplasmic 
and cellular fractions. Th e  results for each fraction were expressed as a percentage of the total 
enzyme activity.
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B-oalactosidase reaction buffer 
60 mM Na*HP04 
50mM 2-mercaptoethanol 
40 mM N aH jPO «
10mM KCI 
1mM M gSO«
Q P N G  solution
4mg/ml ortho-Nitrophenyl p-D-galactoside 
in distilled water
T o  assay B-lactamase activity, 100pl of periplasmic or cellular fractions were mixed with 900pl 
of B-lactamase assay buffer in a cuvette. The  absorbance at 482nm was monitored, using a 
spectrophotometer and chart recorder, as the reaction proceeded and the initial reaction rate 
determined from the gradient of the plot. Again, the results for each fraction were expressed 
as the percentage of the total enzyme activity.
B-lactamase assay buffer 
600pl distilled water 
200pl 0.2M phosphate pH7.0 
lOOpJ Nitrocefin (Difco) at 0.1mg/ml in 
0.1 M phosphate pH7.0
2.7 SDS-PAGE
Periplasmic proteins were separated on S D S  polyacrylamide gels under reducing conditions 
(Laemmli, 1970). Preparations were mixed with an equal volume of 2 x final sample buffer and 
loaded, with or without prior boiling, onto 12.5%  acrylamide gels, with molecular weight
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standards run in parallel (Rainbow protein markers from Amersham International). These were 
run overnight at ~8mA constant current. Gels were stained with 0 .1%  (w/v) C oo mass ie Brilliant 
Blue R250 dissolved in 10% (v/v) acetic acid/40% (v/v) methanol/50% (v/v) distilled water and 
destained in the same solution in the absence of Coomassie Brilliant Blue.
2 x final W m pl? byffgr 
10%  v/v glycerol 
5 %  v/v 2-mercaptoethanol 
3 %  w/v S D S
0.01% w/v bromophenol blue
1 »  S D S -P A G E  ginning bulter 
1.4% w/v glycine 
0 .3%  w/v Tris 
0 .1%  w/v S D S
2.8 Immunoblottlng
Some resolved periplasmic protein samples were electroblotted onto nitrocellulose. Transfer 
was accomplished overnight using 1 x Western Blot buffer (see below) in a  Bio-Rad Trans-Blot 
cell at a constant current of 120mA. After blocking sites of non-specific protein binding (with 
3 %  BSA in PBS), the nitrocellulose filters were washed 3 times in PBS and probed with a 
variety of antisera (e.g. rabbit polyclonal LT-B-spedfic antiserum, BB05 mouse monoclonal) at 
appropriate dilutions (see below) in 0.1%  B S A  in PBS for 1-2 hours at room temperature. After 
3 more washes in PBS, anti-rabbit or anti-mouse immunoglobulins conjugated to Horseradish 
peroxidase (Dakopatts, Glostrup, Denmark) were used as the second antibody. Blots were 
incubated with these conjugates (diluted 1/1000 in 0 .1%  BSA in PBS) for 1-2 hours at room
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temperature. The blots were further washed (5 times) in PBS and then developed with 30mg 
4-chloro-1 - naphthoi (Sigma, Poole. U.K.) dissolved in 10mls methanol/50mls PBS/30pJ H 202 
for 10-20 minutes. Similar protocols were followed for colony blots when screening colonies for 
the expression of desired antigens: colonies were transferred onto circular nitrocellulose filters 
and lysed by inverting them over chloroform for 30minutes. Filters were moistened with PBS 
and blotted against Whatman 3mM paper and excess cellular debris removed by washing in 
PBS. The procedure was then exactly the same as for Western blots.
1 x Western blot buffer 
190mM glycine 
25 mM Tris 
20%  v/v methanol
Antifrxli?? ang antisera
All antisera and antibody preparations were diluted before use, by the stated amount, in PBS 
containing 0 .1%  BSA.
anti-LT-B -  a polyclonal rabbit anti-LT-B  antiserum, raised by Maskell el at., (1987). Used at 
1/500.
antl-HRV -  a polyclonal mouse anti-peptide antiserum, raised by M. Francis (Wellcome 
Research Laboratories). Used at 1/150 after absorption with E. coli lysate (Biorad,
Watford, UK).
anti-114 -  a polyclonal rabbit anti-peptide antiserum, raised against amino add  residues 
364-383 of influenza vims A/Okuda/57 nucleoprotein coupled to Keyhole limpet haemocyanin 
(KLH), a gift from X.M. Gao (Institute of Molecular Medicine, John Radcliffe Hospital, Oxford).
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BB05 - a mouse monoclonal, raised from mice immunised with Bordetella bronchiseptica, 
reactive with P.69 from B. pertussis (Novotny et a!., 1985). Tissue culture supernatant used at
1/20.
VP2-specific monoclonal antibodies - these were raised by P. Barnett and N. Parry (Wellcome 
Research Laboratories) against a peptide containing amino acid residues 24-33 (a T-cell 
epitope) and 156-170 (a  B-cell epitope) from VP2 together with an added cysteine residue. 
Three such monodonals were employed:- 2.7.4.2, 8.5.5.1 and 9.2.5.3. (Barnett and Parry, 
unpublished observations). Concentrated tissue culture supernatants were used at 1/100.
2.9 G^-IInked ELISA*
To  investigate the receptor-binding activity of LT-B-fusion proteins, periplasmic fractions were 
assayed using a G u,-linked ELISA, essentially as described by Svennerholm & Holmgren 
(1978). In these assays, 96 well microtitre plates were coated with 1pg/ml GMI (Sigma) in PBS 
by incubation overnight at 4°C. Unbound material was removed prior to use by washing 3 times 
in PBS. Serial dilutions (varying from 2 fold to 5 fold) of the periplasmic fractions were added 
to the wells and incubated at room temperature for 1 hour. Again, unbound material was 
removed by 3 washes with PBS. Plates were then probed with anti-LT-B for 2 hours at 37°C, 
washed 3 times in PBS and further probed with an appropriate second antibody (as described 
for immunoblotting). Purified L T -B  (a gift from T .  Hirst) was used as a positive control at 2pg/ml 
in PBS. The absoibance of the wells at 450 or 492nm was read on a Titertek multiscan reader
(Flow laboratories).
2.10 Immunological assays
Mice were inoculated with partially purified LT-B  fusion protein or with an attenuated strain of 
S. typhimurium expressing L T -B  fusion proteins. The  immune responses of mice inoculated in 
such a manner were evaluated in a number of ways.
2.10.1 Serum ELISAs
96 well flat-bottomed microtitre plates (Costar, Massachusetts) were coated with 50pJ/well of 
the appropriate antigen preparation (generally 1pg antigen/ml PBS) at 4°C overnight. Plates 
were washed twice in PBS, blocked with 3 %  BSA (incubating at 37°C for 1 hour, 200|il/well) 
and washed again in PBS (three washes). Serial dilutions (usually 3 fold or 5 fold) of control 
and test serum samples were made in 0 .1%  BSA in PBS. 50pl of these dilutions were added 
per well. Plates were then incubated at 37°C, typically for 2-3 hours. Th e  plates were washed 
three times in PBS/0.05% Tween 20 (PBS.T), before the addition of the appropriate 
horseradish peroxidase-conjugated second antibody (50pl/well). After further washing with 
P B S .T  (five washes), the plates were developed with 0.4mg/ml ortho-phenylenediamine 
dihydrochloride (O PD ) dissolved in ELISA substrate buffer (see below), 50pl being added to 
each well. Reactions were stopped by the addition of 12% HjS 0 4 (lOOpl/well). Absorbance at 
450nm or 492nm was read using a Titertek Multiscan reader (Flow laboratories) o r an Anthos 
htll programmeable plate reader.
ELISA substrate butter 
50ml contains:- 
12.2ml 0.1 M citric acid 
12.8ml 0.25M Na*HP04 
25ml distilled water 
20pl 30% H ,0 2 
20mg O PD
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2.10.2 EUSPO T assay
Th e  enzyme-linked immunosorbent spot (ELISPO T) assay, devised by Czerkinsky etal. (1983), 
was used to study the local immune response in the respiratory tract of animals immunised 
intranasally. Lungs were removed from mice asepticaliy and chopped Into a fine paste with a 
scalpel. This was suspended in 'digestion buffer, comprising 0.5 units/ml Coilagenase 
(Boehringer) and 0.25mgs/ml D N Ase I (Boehringer) in PBS/10mM MgCI,, (l-2m l per pair of 
lungs). This mixture was incubated for 1 hour at 37°C with gentle agitation (on an orbital shaker 
set at 80rpm). Following digestion the suspension was passed through a 40 gauge mesh 
(Sigma) to remove the larger pieces of debris. The cell suspension was washed extensively 
in PBS and enriched for lymphocytes on a 'Lymphoprep' (Nycomed Pharma AS, Oslo, Nonway) 
gradient: 5ml of cell suspension were carefully layered onto 10mls of Lymphoprep and spun 
at 3,000rpm for 12 minutes at room temperature in a Sorvall RT6000B centrifuge. The cells 
were recovered from the interface, washed again in PBS and resuspended in Click's medium 
(supplemented with 10%  foetal calf serum, penidllin/streptomycin and L-glutamine at the 
appropriate concentrations). Th e  number of viable lymphocytes in the preparation was 
determined with a Neubauer chamber and 0.5mls were added to the wells of a 24 well tissue 
culture plate (Costar). The plates were incubated at 37°C in an atmosphere of 5 %  C O , for a 
minimum period of 3hrs. After thorough washing in P B S.T, the plates were treated for 2 hours 
at 37°C with isotype-specific goat anti-mouse immunoglobulins. This was followed by 3 washes 
in P B S .T  and incubation for 2 hours at 37°C with afcaline phosphatase conjugated to rabbit 
anti-goat immunoglobulins. The  plates were extensively washed with P B S .T  and finally 
developed with 1mg/ml 5 -brom o-4-chloro-3-indolyl phosphate dissolved in 
2-amino-2-methyl-1-propanol buffer (all purchased from Sigma). Discrete spots could then be 
counted (using a binocular dissecting microscope), which corresponded to the number of 
antigen-specifc antibody secreting cells in each well.
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2.10.3 ft. pertussis  colonisation assay
To  determine the protective effect (If any) of inoculation with LT-B69, mice were challenged 
with an aerosol of B. pertussis (as described in Chapter 6). Protection was assayed by 
comparing the viable count of ft pertussis isolated from the lungs of infected mice in the 
vaccinated and control groups. To  perform these counts lungs were removed aseptically from 
2-3 mice per group and homogenised in 5ml of PBS. Serial tenfold dilutions of the homogenate 
were made in PBS. 20ul drops of these were transferred to CW/btood agar plates, allowed to 
dry and incubated at 35°C for 4-6 days to allow colonies to form. In addition to the above 
assays, mice inoculated with S. typhimurium S L1344 aroA '  aroD ', harbouring plasmids 
directing the expression of various L T -B  fusion proteins, were examined for the development 
of splenic cytotoxic T  cells specific for the heterologous epitopes fused to LT -B . The protocol 
used to investigate cytotoxic T  cell responses are described separately in chapter 4.
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C h a p t e r  3
Construction and ghan»çtgrf«tlgn 9* L f-g ty?lpn prqtelns
3.1 Introduction
The starting-point for the plasmid constructions described in this thesis was pBR D 026 (Maskell 
et al., 1987), a map of which is shown in Figure 3.1.1. This plasmid expresses porcine LT-B 
constitutively under the control of the P1 “anti-tet” promoter of pBR322. Th e  S pe I site located 
at the termination codon at the 3‘ end of the LT-B  gene was used to clone in an oligonucleotide 
encoding a specific sequence of amino acids defining a “hinge" which would permit the in­
frame coupling of foreign peptides to the L T -B  polypeptide. This hinge sequence 
oligonucleotide was designed to incorporate restriction sites for BglII and Spel (Figure 3.1.2). 
In addition, the oligonucleotides contained a one base pair mismatch which prevented the 
reformation of one of the Spel sites and, when inserted in the correct orientation, abolished the 
stop codon at the end of the L T -B  gene. Thus translation proceeds through the 3’ end of the 
L T -B  gene and the oligonucleotide linker to the stop codon at the reformed Spel site. 
Oligonucleotides encoding epitopes can be cloned into the unique BglII and Spel sites, allowing 
expression of the epitopes as fusions to the carboxy terminus of LT-B .
However, there is considerable evidence to show that fusion of foreign peptides to LT-B  can 
profoundly alter the behaviour of the protein. Sandkvist and her collleagues demonstrated that 
even slight alterations, such as the addition of 6 or 1 7 amino acids, to the carboxy terminus of 
L T -B  could radically change the properties of the molecule such that it no longer formed 
pentamers and could not bind to G*,, (Sandkvist et al., 1987). Subsequently, lida and his co­
workers (lida et al., 1989) presented data to suggest that a single mutation, at position 64 in 
the L T -B  amino acid sequence, could interfere with pentamerisation, subunit A -B  interactions 
and G*,,-binding.
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C l a l
Figure 3.1.1 A map of pBRD026. showing the origin of replication and the L T -B  coding region, 
together with the unique Spel site at the 3’ end of the L T -B  gene.
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Thus it was clear that fusion of peptides to L T -B  might after the characteristics of the carrier 
molecule. Most importantly, the ability of L T -B  to bind G y, and hence (according to current 
models) its mucosal immunogenicity, might be diminished or even totally abolished. Careful 
attention to the design of the hinge region was therefore necessary to reduce these difficulties. 
Thus a number of important features were incorporated into these sequences.
Firstly, where possible, amino acids with large charged or aromatic side chains were 
avoided. Secondly, the hinge amino acid sequence was made glycine/proline-rich. Such 
glycine/proline motifs have been identified in several other proteins (Matsushima etal., 1990) 
where they are thought to have an important structural role in defining functional domains. 
Furthermore, the hinge regions of both IgG, (Edelman et al., 1969) and lgG3 (Michaelsen et 
at., 1977) are known to be rich in proline. It is probable that the small molecular radius of 
glycine and proline minimizes structural constraints on the polypeptide. More significant 
perhaps, was the choice of codons specifying these residues, which are only rarely utilised in 
E. coli (Sharp & Li, 1986). Such rare codons are thought to create pauses during translation 
which allow for the correct folding of the nascent polypeptide into functional domains (Purvis 
et al., 1987). The  cis-trans isomerism of proline may also play a role in the creation of these 
translational pauses. Thus it is hypothesised that there is a brief temporal separation of the 
translation of the L T -B  mRNA from the translation of the fused peptide. This allows the LT-B  
moiety to assume its native conformation without structural constraints being imposed by the 
peptide.
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( A )
ApR pBRD026
5' CTTGGGGCCGGGGCCCGAGATCTTTGA 3'
3 ' CCCGGCCCCGGGCTCTAGAAACTGATC 5 '
Cue pBRD026 with Spel and ligate in 
oligonucleotides encoding "hinge" region
( B )
B g l l l  Spel
( C )
5'
3'
B a l l I  S pe  1
. AAAAACTTGGGGCCGGGGCCCGAGATCTTTGACTAGTTT. . . 3 ' 
. TTTTTGATCCCCGGCCCCGGGCTCTAGAAACTGATCAAA. . .5 ' 
K N L G P G P E I F D  Stop
LT-B Hinge
Figure 3.1.2 The strategy used to construct the LT-B fusion vector. pFV1, from pBRD026. (A) 
Plasmid pBRD026 was deaved with Spel and synthetic oligonucleotides, with the sequence 
shown, were inserted to form pFV1 (B). The DNA and corresponding amino acid sequences 
are shown (C). The inclusion of unique BgllI and Spel sites allows the insertion of 
oligonudeotides. (with complementary 5' and 3' ends), encoding heterologous epitopes at the 
3’ end of the LT-B  gene.
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3.2 Construction of the LT-B  fusion vector, pFVI
pBRD026 was linearised with Spel. treated with calf intestine akaline phosphatase and gel- 
purified. Synthetic oligonucleotides with the desired sequence were prepared by Jo hn Keyte 
(School of Biological Sciences. University of Nottingham). These were incubated with T4 
polynucleotide kinase in the presence of A T P , annealed and ligated into Sipel-cieaved 
pBRD026, as described in Chapter 2. The ligation products were used to transform E . coll 
HB101. Miniprep plasmid DNA was obtained from -3 6  ampicillin-resistant transformant 
colonies. This was digested sequentially with BgIH and SaiI and the products separated on an 
agarose gel. Recombinant plasmids containing the oligonucleotide insert (with the unique BglII 
site) gave rise to 2 bands, -1 .0  and 4.0kb, whereas plasmids without the insert generated a 
single band only (~5.0kb) corresponding to linearised plasmid. Plasmids which gave the desired 
restriction pattern with BghMSah digests were checked for the retention of an SpeI site by 
digestion with that enzyme.
Plasmids with the expected digestion pattern were investigated further by subcloning a 
2.0kb PstVSat fragment into M13 m pl9 RF D N A. Single stranded DNA was prepared and 
sequenced as detailed in 2.4. In this way the sequence of the synthetic oligonucleotide was 
confirmed and the sequence across the junctions of the construct could be determined, 
revealing the orientation of the insert. One such transformant containing correctly inserted 
oligonucleotides was isolated and termed pFV1. the sequence of which is illustrated in Figure 
3.2.
3.3 Selection of foreign epitopes to fuse to LT-B
Having successfully created a vector suitable for the expression of foreign epitopes as carboxy 
terminus fusions to L T -B  the logical next step was deciding which epitopes to insert into the 
vector. The  following criteria were used in the selection:-
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LT-B coding 
ragion
start of oligonucleotide
BglII Spel 
5' . . .AAAAACTTGGGGCCGGGGCCCGAGATCTTTGACTAGTTT. 
3' . . .TTTTTGATCCCCGGCCCCGGGCTCTAGAAACTGATCAAA.
G P G P E I F D  stop. . .N  lV g
one base pair mismatch
.3'
.5'
The determined DNA sequence across the 
junctions of the construct.
A C G T
“ "Stop" TAG
Start o f--------------
oligonucleotide
hinge-coding
region
Figure 3.2 Th e  predicted and determined DNA sequence across the junctions of pFV1.
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1 ) the epitopes should be at least moderately well-characterised in other models, preferably 
by researchers at Wellcome as this would allow access to valuable reagents (such as antisera, 
monoclonal antibodies, synthetic peptides) and information,
2) the epitopes should be derived from antigens from pathogens of mucosal surfaces, 
because of the nature of the mucosal immunogenicity of LT-B  discussed in the introduction,
3) the antigens from which the epitopes were derived should be the targets for protective 
immune responses,
4) the epitopes used should encompass a number of different types, ideally both B-cell and 
T-cell, from bacterial and viral antigens, to investigate as many aspects as possible of the 
immunogenicity of the resulting fusion proteins.
5) the amino acid and/or nucleotide sequence of the epitope must be available, otherwise 
the correct oligonucleotides could not be synthesised,
6) the epitope should be mapped to a detailed level (e g. less than 30 amino acid residues) 
to allow the entire epitope to be encoded by an easily synthesised oligonucleotide.
Using these criteria, the following epitopes were selected:-
B-cell epitopes
a) The  monoclonal antibody BB05 binding-site from P.69, a B. pertussis surface-associated 
protein. Antibodies to this antigen have been shown to protect piglets against B. bronchiseptica- 
mediated disease (Novotny et al., 1985).
b) An epitope present in the major capsid protein (VP2) of human rhinovirus type 2 (H R V  2), 
(Clarke et al., 1991). A  large panel of monoclonal antibodies were raised against a synthetic 
peptide derived from the V P 2  sequence and used to define the epitope (Barnett & Parry, 
unpublished observations).
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T  cell epitopes
a) peptide 110 -  a peptide from influenza A  virus A/Okuda/57 nucleoprotein (N P), which acts 
as a target for cytotoxic T  lymphocytes (C T L ) in BALB/c mice with the H-2* haplotype (Taylor 
etal., 1987).
b) peptide 167 -  a peptide from the same protein which is recognised by T  helper (Th ) cells in 
B.10 S  mice (H-2* haplotype). (Gao et al., 1989).
c) peptide 114 -  again, a peptide from nucleoprotein, which is a target for C T L  in B6 (H -Z6) 
mice (Gao, unpublished observations).
3.4 Construction of the LT-B/epItope fusion plasmids
Th e  procedure followed was essentially the same for the construction of all the recombinant 
fusion plasmids. Large scale preparations were made of pFV1. These were digested 
sequentially with BglII and Spel (in the appropriate buffers) and gel-purified. Oligonucleotides 
(synthesised by Hugh Spence and Martin Carrier at Wellcome Research Laboratories) were 
incubated with T4  polynucleotide kinase in the presence of A T P , annealed and ligated into the 
vector preparations as described in 2.5.5. The sequences of these oligonuceotides are shown 
in Figures 3.4.1-3. These oligonucleotide sequences were designed to incorporate restriction 
sites. Where possible these were unique. This would allow restriction digest patterns to be used 
to screen for recombinant plasmids with the desired insert. Recombinant plasmids containing 
oligonucleotide inserts were obtained and were analysed by sub-cloning into M13 mp19 prior 
to dideoxy sequencing as before. A s  two restriction sites were used to clone in the 
oligonucleotides, only one orientation of insertion was possible. DNA sequencing was 
considered essential to preclude the possibility of an error in the synthesis of the
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"hinge"
LT-B coding 5' . . .AAAAACTTGGGGCCGGGGCCCGAGATCGCTCCGCAGCCG 
region 3' . . .TTTTTGAACCCCGGCCCCGGGCTCTAGCGAGGCGTCGGC
N L G P G P E  I A P Q P
War I
GGTCCGCAGCCGCCGCAGCCGCCGCAGCCGCAGCCGGAGGCGCCGGCT
CCAGGCGTCGGCGGCGTCGGCGGCGTCGGCGTCGGCCTCCGCGGCCGA
G P Q P P Q P P Q P Q P E A P A
CCGCAGCCGGACTAGTTT---3'
GGCGTCGGCCTGATCAAA. . .5' 
P Q P D Stop
The determined DNA sequence across 
the junctions of the construct.
A C G T
—r — —  "Stop" TAG
G/C-rich
BB05
epitope­
coding
region
Hinge­
coding
region
Figure 3.4.1 The predicted amino acid sequence and the predicted and determined DNA 
sequences across the junctions of the pFV1::69 construct.
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"hinge"
LT-B coding 5' . . .AAAAACTTGGGGCCGGGGCCCGAGATCGTTGCT 
region 3 ' . . .TTTTTGATCCCCGGCCCCGGGCTCTAGCAACGA
N L G P G P E I V A
Nae I
CACAAATCTTGCCTGCCGGCTTGCGTTTACGGTCCGGACTAGTTT . . . 3 ' 
GTGTTTAGAACGGACGGCCGAACGGCAAATGCCAGGCCTGATCAAA. . 5 ' 
H K S C L P A C V Y G P D  Stop
The determined DNA sequence across the 
junctions of the construct
A C G T
■♦—"Stop" TAG
Epitope­
coding
region
Hinge-
coding
region
Figure 3.4.2 The predicted amino acid sequence and the predicted and determined DNA 
sequences across the junctions of the pFV1::167 construct.
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"hinge"
LT-B coding 5 ' . . . AAAAACTTGGGGCCGGGGCCCGAGATC 
region 3 '  .. . TTTTTGATCCCCGGCCCCGGGCTCTAG
N L G P G P E I
Mill I
ACGCGTCTGAACCCGGACTAG. . .3' 
TGCGCAGACTTGGGCCTGATC. . . 5 ' 
T R L N P D Stop
"hinge"
LT-B coding 5 '__ AAAAACTTGGGGCCGGGGCCCGAGATCCAGATCGCTTCT
region 3' .. . TTTTTGATCCCCGGCCCCGGGCTCTAGGTCTAGCGAAGA
N L G P G P E I Q I A S
Sac I
AACGAAAACATGGACGCTATGGAGAGCTCTACTCTGGAACTGCGTGACTAG-- 3 '
TTGCTTTTGTACCTGCGATACCTCTCGAGATGAGACCTTGACGCACTGATC. . .5' 
N E N M D A M E S S T L E L R D  Stop
C
LT-B coding 5 ' 
region 3'
"hinge"
. AAAAACTTGGGGCCGGGGCCCGAGATCACCTACCAGCGT 
>TTTTTGATCCCCGGCCCCGGGCTCTAGTGGATGGTCGCA 
N L G P G P E I T Y Q R
Mlu I
ACGCGTGCTCTGGTTCGCACTGGTATGGACCCGGACTAG.. .3' 
TGCGCACGAGACCAAGCGTGACCATACCTGGGCCTGATC• . .5' 
T R A L V R  T G M D P D  Stop
Figure 3.4.3 The DNA and amino acid sequences across the junctions of the pFV1 ::VP2 (A), 
pFV1::114 (B) and the pFV1::110 (C ) constructs.
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oligonucleotides and to confirm the in-frame insertion of the epitope-encoding sequences. The 
resulting recombinant plasmids are detailed in Table 3.4.
Table 3.4 The chimeric proteins encoded by the various LT-B fusion plasmids
Recombinant Recombinant Heterologous
plasmid polypeptide Epitope
pFV1 LT-BH None ("hinge")
pFV1::110 LT-B110 p110, T  cell
pFV1::114 LT-B114 p114, T  cell
pFV1::167 LT-B167 p167, T  cell
pFV1 ::69 LT-B69 BB05, B ce ll
pFV1 ::VP2 LT-BV P2 VP2, B  cell
3.5. In vitro characterisation of the fusion proteins In periplasmic fractions of E. coll
The  initial step in the in vitro characterisation of the different L T -B  chimerae w as to ascertain 
whether these proteins retained the properties of native LT-B : transport to the periplasmic 
space and assembly into pentamers. To  answer this question, periplasmic fractions were 
prepared from E. coli cultures harbouring the various plasmids detailed in Table 3.4, as 
described in Chapter 2. Periplasmic fractions from HB101 (p F V l) and HB101 (pFV1 ::69) were 
obtained. Th e  samples were loaded directly onto an SDS-polyacrylamide gel, or boiled for 10 
minutes first, and separated by running the gel overnight. The results are shown in Figure 3.5. 
It was found that the products of pFV1 (L T-B H ) and pFV1::69 (L T-B 6 9), are soluble and 
transported into the periplasm of E. coli, where they are reasonably stable.
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1 2 3 4 5 6 7 8
97.4
69.0
30.0 ______  ______
Figure 3.5 S D S-P A G E analysis of periplasmic fractions from E. coli. Lane 1. HB101 (unboiled); 
lane2, HB101 (boiled); lane3. HB101 (pMMB68) (unboiled); lane 4. HB101 (pMMB68) (boiled); 
lane 5. HB101 (pFV1) (unboiled); lane 6, HB101 (pFV1) (boiled); lane 7, HB101 (pFV1::69) 
(unboiled); lane 8, HB101 (pFV1:;69) (boiled). The LT -B - and LT-B69-specific bands are 
arrowed. Numbers on the left indicate the positions of molecular weight standards with the size 
(in kiloDaltons) shown.
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Furthermore they assemble into pentamers which dissociate into the constituent monomers on 
boiling. Pentameric L T -B H  migrates as a polypeptide of 46 kDa (Hirst etal., 1988) and appears 
to have a rather higher Mr than that of native human L T -B  (h LT-B ), as expressed by the 
construct pMMB68 (FOrste etal., 1983 and Sandkvist etal., 1987). The monomeric polypeptide 
migrates as a protein of -1 3  kDa and also appears to have a higher M, than that of monomeric 
hLT-B . The calculated M, of hLT-B  is just under 12.0 kDa, corresponding to a 55 kDa 
pentamer. That of L T -B H  is 13 kDa, equivalent to a pentamer of about 60 kDa. These 
differences are just 1.0 kDa and 5.0 kDa, thus the fact that these can be detected shows the 
considerable resolution which can be achieved with S D S -P A G E , even on a non-gradient gel.
The fusion protein, LT-B69, runs as a pentamer of -9 0  kDa and as a monomer of -1 8  kDa. 
This is a reflection of the coupling of the BB05 epitope, which has a calculated M, of 3 kDa. 
However the simple addition of 3 kDa to the molecular weight of the protein is insufficient to 
explain its low mobility. As noted by See & Jackowski (1989), a number of proteins with high 
proline content have abnormally high molecular weights as determined by S D S -P A G E  (Starr 
& Offer, 1983). The  same is true of the P.69 protein from B. pertussis, from which the BB05 
epitope was taken. Although the protein has a calculated molecular weight of 60 kDa (Makoff 
et a!., 1990), it has an apparent mobility of 69 kDa. This discrepancy is thought to be due to 
the high proline content, which is particularly notable in the region of the BB05 epitope. Thus 
it would seem that the high proline content of the BB05 epitope affects the migration of LT-B69 
as a whole.
The level of expression of the chimeric proteins was low (just a few %  of total protein in 
periplasmic fractions) but no lower than might be expected in comparison to other proteins 
expressed from the P1 (*anti-tet*) promoter (e.g. Maskell et al., 1987).
One other feature of interest is apparent in Figure 3.5. In tracks 5-8 a prominent low M, 
(<14.3 kDa) polypeptide is apparent which is not present in tracks 1-4. Whilst all the samples 
were prepared from E. coli HB101 cultures, the samples in tracks 1-4 were prepared from an 
HB101 strain used at Leicester University, whilst the samples in tracks 5-8 were prepared from 
the HB101 strain in use at the Wellcome Research Laboratories. Thus there is at least one
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distinction between the two strains: the presence or absence of this polypeptide in the 
penpiasmic space. There may well be other differences.
That these proteins were truly of periplasmic origin was confirmed by performing f)- 
galactosidase assays upon the periplasmic and cellular fractions (obtained in the course of the 
experiments) as described in Chapter 2. p-lactamase assays were also performed on these 
fractions to estimate the proportion of periplasmic proteins released. Typical results are shown 
below in Table 3.5.
Table  3.5 Relative enzyme activities In the cellular and periplasmic fractions of E. c o ll
%  p-galactosldase %  p-lactamase
activity activity
pFV1 cells 100 52
p F V l periplasm 0 48
pFV1 ::69 cells 100 61
pFV1 ::69 periplasm 0 39
p-galactosidase is an enzyme whose distribution is restricted solely to the cytoplasmic 
compartment, and therefore it was only detected in the cellular sonicate. Its complete absence 
from the periplasmic fractions is evidence that the integrity of the inner membrane is not 
impaired by the lysozyme/EDTA treatment. Therefore any proteins present in these fractions 
must be periplasmic or membrane-associated in nature. It has been shown previously that 
h L T-B  is truly periplasmic in nature and not membrane-associated (Hirst et at., 1984a).
In contrast, ^-lactamase is efficiently transported to the periplasmic space. Clearly, this is 
essential if the enzyme is to be protective against p-lactam antibiotics, which act on penicillin­
binding proteins present in the periplasm. The  results of the p-lactamase assays demonstrate 
that, in general, rather less than half of the total cellular pool of p-lactamase is released by the 
lysozyme/EDTA treatment. Thus, if one assumes all p-lactamase to have a periplasmic location,
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the sphaeroplasting protocol employed yields less than fifty percent of total periplasmic protein. 
However, it does ensure that there is no contamination by cytoplasmic protein in the samples.
3.6 Immunoblottlng
Periplasmic fractions were prepared from E. coli HB101 cultures harbouring the novel 
constructs detailed in Table 3.4. These were subjected to S D S -P A G E  and transferred to 
nitrocellulose. The filter was probed with anti-LT-B polyclonal antiserum. The results are shown 
in Figure 3.6.1. As experienced previously with LT-B69, all the fusion proteins formed 
pentameric complexes, ranging in apparent molecular weight from about 60 kDa to 97 kDa (i.e. 
higher than would be expected from L T -B  or LT-BH  alone). Upon boiling these bands disappear 
simultaneously with the formation of new bands which migrate with apparent molecular weights 
ranging from ~13 kDa to 18 kDa, which correspond to the constituent monomers of the fusion 
proteins (again, higher than would be expected from monomers of L T -B  or L T -B H ). It would 
seem that the pentameric form of the fusion proteins is subject to degradation -  the bands are 
diffuse and poorly defined. In contrast the monomeric polypeptides form quite well defined 
bands. This is slightly surprising because many of the epitopes of C T -B  and L T -B  are known 
to be heat-labile and are destroyed by boiling (Kazemi and Finkelstein, 1990). Possibly the 
boiling results in just a few nearly identical stable forms of the respective polypeptides (i.e 
greater homogeneity), leading to greater localisation of the material on the gel and 
corresponding blot. An alternative explanation for the faint staining of the bands (if not their 
diffuse nature) is that the addition of the heterologous epitopes to the C  terminai affects the 
antigenicity of the L T -B  moiety, perhaps masking some of the L T -B  epitopes when present in 
a pentameric complex. Upon boiling of the protein, yielding the constituent monomers, these 
epitopes are unmasked and made available for binding anti-LT-B antibody.
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Figure 3.6.1 Immunoblot analysis of periplasmic fractions of E. coli. Fractions were prepared 
as described in 2.7.1. These were subjected to S D S -P A G E  and electroblotted onto a 
nitrocellulose filter. This was probed with a polyclonal LT-B-specific antiserum as detailed in 
2.9. Lanes 1 and 6. HB101 (pFV1::VP2); lanes 2 and 7, HB101 (pFV1 ::110); lanes 3 and 8. 
HB101 (p FV I ::167); lanes 4 and 9, HB101 (pFV1::114); lanes 5 and 10. HB101 (pFV1::69), 
Lanes 1 -5 loaded with unboiled samples, lanes 6-10 loaded with boiled samples. The numbers 
on the right refer to pre-stained molecular weight standards with the size shown in kiloDaltons.
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The identity of the LT-B69  and LT-BVP2 fusion proteins was confirmed in subsequent 
immunoblotting experiments using sera specific for the respective fused epitopes. Figure 3.6.2 
shows peripiasmic fractions from HB101 (pFV1) and HB101 (pFV1::69) probed with the BB05 
mAb. This monoclonal antibody is seen to react solely with the sample prepared from HB101 
(pFV1::69). The high avidity of this reagent enables detection of a wide range of breakdown 
products in the unboiled sample. Th e  majority of the material however is present as pentameric 
LT-B69, with an apparent molecular weight of -9 0  kDa, as detected by the LT-B-specific 
antiserum. Upon boiling only a single band is detected. This equates to the 18 kDa band 
similarly detected with LT-B-specific antiserum and represents monomeric LT-B69. Thu s the 
presence of the L T -B  carrier molecule does not appear to inhibit the antigenicity of the BB05 
epitope, at least in a denatured form in a Western blot.
Similarly, peripiasmic fractions were prepared from HB101 (pFV1) (boiled sample only) and 
HB101 (pFV1::VP2) (both boiled and unheated samples). These were resolved by S D S -P A G E  
and transferred to a nitrocellulose filter. This filter was probed with a  VP2 peptide-specific 
polyclonal antiserum (a gift from  M . Francis, Wellcome Research Laboratories). The results are 
shown in Figure 3.6.3. It can be seen from this figure that the serum does not react with the 
HB101 (pFV1) extract nor, surprisingly, with the unboiled HB101 (pFV ::V P2) extract. In contrast, 
the boiled extract gives a band at the expected position, which is readily bound by the 
antiserum. Why this should be so is unclear. It may be that, unlike the LT-B 6 9  fusion, there is 
some sort of steric hindrance in the pentameric complex (even in the denatured form), which 
prevents the VP2 epitope from  being exposed. In this respect it might be significant that the 
sequence of the added epitope is very short (just 6 extra amino acid residues), whereas the 
fused epitopes of the other L T -B  chimerae are quite long (20-30 extra amino acid residues) in 
comparison.
Similar experiments, using polyclonal antisera specific for the 110 or 167 epitopes, failed 
to detect the respective fusions on Western blots, despite the increased molecular weight 
apparent in blots probed with anti-LT-B  antiserum. Possible explanations for this observation 
are discussed in the following section.
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Figure 3.6.2 Immunoblot analysis of periplasmic fractions of E. coli HB101 pFV1 and HB101 
pFV1::69. Periplasmic fractions were obtained as described in 2.7.1, subjected to S D S -P A G E  
and electroblotted onto a nitrocellulose filter (as detailed in 2.8 and 2.9). This filter was probed 
with the mouse monoclonal antibody BB05. Lane 1. HB101 (pFV1) (unboiled); lane 2, HB101 
(pFV1::69) (unboiled); lane 3. HB101 (pFV1) (boiled); lane 4. HB101 (pFV1::69) (boiled). The 
positions of pre-stained molecular weight standards are shown on the right.
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Figure 3.6.3 Immunoblot analysis of perlplasmic fractions from E. coli HB101 (pFV1) and 
HB101 (pFV1 ::VP2). Samples of periplasmic proteins were prepared, separated by SD S-PAG E 
and electroblotted onto nitrocellulose as described previously. The filter w a s  probed with a 
polyclonal VP2 peptide-specific antiserum. Lane 1. HB101 (pFV1 ::VP2) (boiled); lane 2, HB101 
(pFV1::VP2) (unboiled); lane 3. HB101 (pFV1) (boiled). Numbers on the right refer to the 
position of standards with the molecular weight shown in kiloDaltons.
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3.7 Gw-linked ELISAs
The observation that the various L T -B  chimeric proteins formed pentamers was encouraging 
because it is believed that only L T -B  in the pentameric form has a high affinity for Gy, (which 
in turn is believed to be central to the immunogenicity of LT-B ). Svennerholm & Holmgren 
(1978) devised a Gy,-linked E L IS A  method to investigate Gy,-binding by C T  and LT. This 
method was adapted (as described by Maskell et a!., 1987) to study the affinity for Gy, of the 
various L T -B  fusion proteins. In one such experiment, periplasmic extracts were prepared from 
E. coli HB101, HB101 (pFV1) and HB101 (pFV1::69). These were adjusted to an equal 
concentration of total protein, and added to Gy,-coated or blank, uncoated 96 well flat-bottomed 
microtitre plates. The samples were serially diluted 1:3 down the plate using PBS as the diluent 
and then probed with rabbit anti-LT-B  antiserum (the assay method is described in detail in 
Chapter 2). The absorbance was read and plotted against dilution. The results are shown in 
Figure 3.7.1. This shows that on plates not coated with Gy„ very little L T -B  could be detected 
whether the antigen in question was LT -B H  or LT-B69. Equally, there was no antibody bound 
if a periplasmic fraction from HB101 alone was applied to a GM,-coated plate. If, however, 
fractions from HB101 (pFV1) or HB101 (pFV1::69) were applied to a Gy,-coated plate LT-B  
was readily detected, indicating that LT -B H  and LT-B69 both retain the ability to bind Gy,. 
Purified L T -B  (a generous gift from T .  Hirst, University of Leicester) was included at 1pg/ml as 
a positive control. Thus, as was experienced with the immunoblotting experiments, the 
presence of the BB05 epitope at the C-terminal of L T -B  does not interfere with the antigenicity 
of the L T -B  moiety nor, more importantly, does it greatly inhibit binding of Gy,.
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Figu re  3.7.1 The  ganglioside-binding activities of L T -B H  and LT-B69 were investigated by an 
EL IS A  technique. Periplasmic fractions from E. coli were obtained by the method previously 
described, adjusted to an equal concentration of total protein and applied to G*,,-coated 
microtitre plates (open symbols) or uncoated blank plates (filled-in symbols). These were then 
probed with polyclonal anti-LT-B antiserum and processed following standard ELISA protocols. 
HB101 (A, A); HB101 (pFV1) ( O , « ) ;  HB101 (pFV1::69) ( □ , ■ )  and purified L T -B  alone Q .
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In a similar assay (the results of which are shown in Figure 3.7.2), the antibody probe used 
was the monoclonal antibody BB05. As expected, no reactivity was observed from HB101 
(pFV1) extracts on either blank or Gy,-coated plates. In contrast, LT-B69  could be detected 
easily, but only on a Gy,-coated plate, once again demonstrating the specificity of the assay. 
Furthermore, this proves that the L T -B  carrier molecule does not significantly interfere with the 
antigenicity of the BB05 epitope in a nearly native state (the fusion protein is presumably in a 
slightly different conformation if bound to Gy, than if in free solution) whilst the earlier 
immunoblotting experiment with the same mAb probe had shown that this was true if the 
protein was highly denatured.
Similarly, periplasmic fractions from HB101 (pFV 1) and HB101 (pFV 1::V P2) were 
compared. These were added to G MI-coated plates and probed with one of three mouse 
monoclonal antibodies (termed 2.7.4.2,8.5.5.1 and 9.2.5.3 respectively). These were prepared 
by P. Barnett (Wellcome Research Laboratories; Barnett & Parry, personal communication), 
having been raised against a peptide consisting of amino add residues 24-33 (a T  cell epitope) 
and 156-170 (a B cell epitope) of VP2, together with an added C  terminal cysteine residue to 
facilitate coupling of the peptide to keyhole limpet haemocyanin (KLH). Tw o  of these 
monoclonals (2.7.4.2 and 8.5.5.1) could detect the LT-B V P 2  fusion protein on ganglioside 
coated plates (Figure 3.7.3, graphs A  and B) whilst the other (9.2.5.3) could not (data not 
shown). This difference may be due to the first two antibodies recognising a particular peptide 
conformational epitope which is conserved in the fusion protein whilst the latter antibody 
recognises a conformational epitope, unique to the peptide-KLH conjugate against which it was 
raised, which is not represented in the LT-BV P2 fusion (when bound to Gy,). In a similar 
experiment, a polyvalent VP2 peptide-specific antiserum (described in 3.6), was used as a 
probe. Th e  results are shown in Figure 3.7.3, graph C . It is clear from these results (Figure
3.7.3, graphs A, B and C ) that the short VP2 peptide sequence is present in the LT-BV P 2 
fusion and is accessible to antibody when the molecule is in a near native state. In addition, 
an assay was performed on the same periplasmic fractions using the rabbit polyclonal anti-LT-B 
antiserum as the probe. The results are shown in Figure 3.7.3, graph D.
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Figure 3.7.2 The  identity and ganglioside-binding activity of the LT-B69  fusion protein was 
confirmed by means of an EL IS A  (described in 2.10). Periplasmic fractions were prepared from 
E. coli, adjusted to an equal concentration of total protein and allowed to react with microtitre 
plates coated with G MI (open symbols) or microtitre plates left uncoated as blanks (filled-in 
symbols). The plates were then probed with the monoclonal antibody. BB05. HB101 (pFV1) 
((> .• ); HB101 (pFV1 ::69) (□ . ■ ) .
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Figure 3.7.3 Th e  identity and G*,,-binding activity of LT-BV P 2 was confirmed in a number of 
ELISAs. Periplasmic fractions were prepared from E. coli HB101 (pFV1::VP2) and control 
samples were prepared from HB101 (pFV1). These were adjusted to an equal concentration 
of total protein, applied to G*,,-coated microtitre plates and probed with a variety of antibodies. 
HB101 (pFV1::VP2) (• ) and HB101 (pFV1) (O ) were probed wth:-
A) VP2 peptide-specific monoclonal antibody 1.2.5.3
B) VP2 peptide-specific monoclonal antibody 8.5.5.1
C ) VP2 peptide-specific polyclonal antiserum
D) LT-B-specific polyclonal antiserum
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There is noticeabiy less binding of the anti-LT-B antibodies by LT-BV P2 than by LT -BH . This 
may be due to diminshed affinity for G y, as a result of the presence of the heterologous fused 
epitope. An alternative explanation is that there is an equal amount of bound antigen but less 
binding of the LT-B-specific antibodies. This seems unlikely because such an effect is not 
marked with the other L T -B  fusion proteins in which the fused epitopes are much larger than 
that in LT-BVP2. Other G M1-linked ELISAs were performed on periplasmic fractions prepared 
from E . coli HB101 pFV1::114 and control samples from HB101 (pFV1). These samples were 
probed with a peptide 114-specific polyclonal rabbit antiserum (a kind gift from X.M. Gao, 
Institute of Molecular Medicine) (Figure 3.7.4, graph A) or polyclonal anti-LT-B antiserum 
(Figure 3.7.4, graph B). Th e  peptide 114-specific antiserum detected L T -B 1 14 on a Gy,-coated 
plate, but not LT-BH , thus confirming the identity of the fusion protein. Anti-LT-B  antiserum 
reacted equally well with L T -B H  and LT-B114, indicating that the LT-B114  fusion protein and 
L T -B H  had comparable G M1-binding activities, assuming they were bound to by anti-LT-B 
antibody with equal affinity.
A s  previously experienced in immunoblotting experiments, polyclonal antisera specific for 
p110 o r p i 67 failed to detect the respective fusion proteins in ELISAs (data not shown). The 
D N A  sequence of pFV1::110 and pFV1::167 was confirmed previously so one would expect 
correct expression of the fusion proteins. Therefore, it would seem that the likely explanation 
for this failure to detect expression is that the LT-B110 and LT-B167  fusions are more 
susceptible to degradation than the other fusion proteins, such that short fragments containing 
the relevant epitopes run off the bottom of gels during S D S-P A G E (and so are not present on 
the resulting blots) and are unable to bind to Gy, (and so are not detected in G ui-linked 
E L IS A s ). Alternatively, the major epitope-specific antibodies in the antisera may not have 
recognised the heterologous epitopes within the context of the L T -B  fusion protein (whilst they 
did bind to the synthetic peptides, corresponding to the epitopes, when adsorbed onto microtitre 
plates).
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Figure 3.7 .4  The identity and G M1-binding activity of LT -B 1 1 4  was confirmed by means of a 
G M1-linked ELISA. Periplasmic fractions were prepared (as described previously) from E. coll 
HB101 (p F V 1 ) and HB101 (pFV1 ::114). These were applied to G M1-coated microtitre plates and 
probed with heterologous epitope-specific (graph A ) or LT-B-specific (graph B ) antisera.
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3.8 Summary
The results obtained from the various immunoblotting experiments and ELISAs performed in 
order to determine the behaviour of the L T -B  chimeric proteins in vitro are summarised in Table
3.8 below.
Table 3.8 Confirmation of the Identities and G^-blndlng properties of the various LT-B  
fusion proteins
Recombinant
Protein
Detection by:-
Immunoblot G*, ELISA 
L T -B  Epitope LT-B Epitope
LT-BH + N.D. + N.D.
LT-B110 + + -
LT-B114 + N.D. + +
LT-B167 + + *
LT-B69 + + + *
LT-BVP2 + + + +
N.D. -  Not done. +  -  detected. -  -  not detected
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Th e  results obtained from the in vitro characterisation of the fusion proteins show that certain 
additions to the C  terminal of L T -B  do not necessarily lead to the loss of properties associated 
with the native molecule, namely accumulation in the periplasmic space of E. coli, formation 
of pentamers and the ability of the pentameric complex to bind to its ganglioside receptor. It 
is impossible to say to what extent the preservation of these properties is dependent upon the 
inclusion of the hinge region between the carrier molecule and th e  fused epitope. One way to 
determine the significance of the hinge might be to design oligonucleotides corresponding to 
the sequences of the fused epitopes, such that they could be ligated in directly at the SpeI site 
of pBRD026. One could then compare the resulting fusion proteins with those expressed by 
pFV1 and its derivatives.
Another observation which can be made is that the chimeric L T -B  monomers are capable 
of pentamerisation in the absence of the A-subunit. This phenomenon has been noted 
previously for native L T -B  (Sandkvist et al., 1987). Indeed, it w ou ld  be interesting to discover 
whether the chimeric L T -B  molecules were still capable of interacting with the A-subunit. The 
same authors (Sandkvist et al., 1987) found that the addition of seven amino adds to the C  
terminal of L T -B  prevented the molecule from immunoprecipitating in the presence of A-subunit- 
specific antiserum (when co-expressed with A-subunit by E. coli), whilst the altered molecule 
was readily precipitated by anti-A/B-subunit antiserum, implying that the A-subunit would no 
longer associate with the altered B-subunit. It might be argued that, should L T -B  fusion proteins 
ever be used in the production of human or animal vaccines, an  inability of the B-subunit to 
associate with A-subunit is to be preferred so as to prevent the possibility of toxicity (even 
though it is difficult to envisage conditions where there might b e  contamination by exogenous 
toxin A-subunit).
A  further point to be considered is the location of the C  terminal of L T -B  in terms of whether 
it is surface-exposed or buried within the molecule. Considering the significance of the C  
terminal in subunit-A/B interactions it would seem probable that the C  terminal is surface- 
exposed. Certainly the G ^-linked ELISA results obtained using heterologous epitope-specific 
antibody probes would seem to indicate that, in general, fusion to L T -B  has little effect on the
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accessibility or antigenicity of the epitopes. Indeed, the surface-exposed nature of the C  
terminal of L T -B  has recently been confirmed in the structure of the molecule reported by 
Sixma eta!., (1991).
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C H A P T E R  4
inoculation of mice with attenuate« S. tvphlm urtum  gp. harbouring LT-B  fyylon prptgln 
expression plasmids
4.1 Introduction
A  number of approaches have been employed in an attempt to stimulate mucosal immune 
responses against bacteria. The simplest involve the use of the oral route to administer 
antigens which elicit good systemic responses when given parenterally. such as killed whole 
cell bacterial vaccines. Numerous studies have been performed using potential vaccines 
against such bacterial pathogens as Streptococcus mutans (Bonta et at., 1979) and Vibrio 
cholerae (whole cell vaccine given in conjunction with purified antigen; Svennerholm & 
Holmgren, 1986).
Alternatively, mucosal immunity can be generated by the administration of live, 
spontaneously-arising, attenuated mutant strains, such as the avirulent T M Istrati strain of 
Shigella flexneri (Istrati et at, 1967) or the attenuated streptomycin-dependent (Sm D) strain of 
the same organism (Mel et al., 1971). Considerable effort has been devoted to the 
development of an attenuated Salmonella typhi strain suitable for use as a live oral vaccine 
against typhoid fever in humans. Several attenuated strains of other species of Salmonella 
have also been evaluated, with varying degrees of success. For instance, temperature-sensitive 
strains, unable to grow at the tempertaure of the host, have been reported for S. enteritidis 
(Fahey & Cooper. 1970a,b) and for S. typhimurium C5 (Hormaeche et al., 1981). As with 
Shigella, SmD strains have also been described, notably attenuated strains of S. typhi 
(Reitman, 1967; Mel et al., 1974). Th e  Reitman strain was found to be safe and efficacious in 
humans, but practical problems prevented its adoption as a vaccine (Levine et al., 1976). 
Germanier and Furer (1975) subjected S. typhi strain Ty2 to chemical and ultraviolet 
mutagenesis and isolated a galE  mutant. Th e  galE  gene encodes the enzyme uridine
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diphoshate (U D P ) galactose-4-epimerase, which catalyses the conversion of UDP-glucose to 
UDP-galactose. UDP-galactose is an essential component of smooth lipopolysaccharide (LPS), 
thus ga/E mutants can only make rough LPS, a characteristic associated with attenuation. (If 
exogenous galactose is present, the galE  mutants can convert it into UDP-galactose via 
galactose-1-phosphate, so allowing the synthesis of smooth LP S . However, exogenous 
galactose is toxic because galactose-1-phosphate accumulates intracellularly, resulting in cell 
lysis). The galE  mutant obtained by Germanier, S. typhi Ty21a, was found to be safe and 
protective in human volunteers, affording protection in two large field trials (in Egypt and Chile) 
ranging from 96-67% , (Wahdan et al., 1982 and Levine et al., 1987 respectively). However, 
subsequent work (Hone et al., 1988) proved that the galE  mutation was not the major 
attenuating lesion in S. typhi Ty21a. Partly as a result of the uncertainty surrounding the 
genetic basis of attenuation in the strain and partly because of a number of practical 
considerations (vaccine instability, variable efficacy and the requirement for multiple doses), it 
was not widely adopted for routine vaccination.
This experience highlights the advantage of a rather different approach (which has already 
been used with considerable success by a number of research groups), that of utilising 
recombinant D N A technology to introduce defined mutations into the genome of pathogenic 
organisms, so as to bring about attenuation in a rational manner. Th is  method is more 
advantageous than evaluating spontaneous or chemically-induced mutants because the 
introduction of defined deletion mutations at different, widely-separated loci on the bacterial 
chromosome makes reversion an extremely unlikely possibility. In addition, it allows for a wide 
spectrum of attenuation, from full virulence to complete avirulence, depending on the deletions 
made. Thus an optimal level of attenuation can be achieved, at which the organism does not 
cause any symptoms but persists for long enough in sufficient numbers to elicit strong immune 
responses. Amongst the genes which have been made the targets for deletion or inactivation 
in Salmonella spp. are cya and crp (Curtiss & Kelly, 1987), phoP/phoO  (Miller et al., 1989), htrA 
(Johnson et al., 1990), om pR  (Dorman et al., 1989) and several of the aro genes (Hosieth & 
Stocker, 1981, Dougan et al., 1988). These latter genes encode the essential enzymes
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controlling the biosynthesis of aromatic amino acids, and the compounds dihydroxybenzoate 
(D HB) and p-aminobenzoic acid (PA BA) -  essential intermediates in the synthesis of 
nucleotides.
As well as the obvious benefits of an oral typhoid vaccine, such attenuated strains of 
Salmonella have been demonstrated to be ideal carriers of heterologous antigens to both the 
systemic and the secretory immune systems of experimental animals (reviewed by Dougan & 
Tite, 1990). This is a  reflection of the course of infection which results from oral inoculation of 
certain strains of mice with S. typhimurium. The  organism penetrates to deep tissues (such as 
the spleen) after specific invasion of the G A L T  (Carter & Collins, 1974). Thus 
immunocompetent cells from both the systemic and the local immune systems directly 
encounter antigen. As a result, such bacterial vectors are capable of stimulating serum and 
secretory antibody responses and cell mediated immunity. There are reports of avirulent 
Salmonella strains having been used to elicit secretory and humoral responses in mice to E. 
collL T -B  and K88 fimbriae (Maskell etal., 1987 and Stevenson & Manning, 1985 respectively), 
Shigella sonnei O-antigen (Black et al., 1987) virulence determinants from Streptococcus 
mutans (Curtiss et al., 1986) and cell mediated immune responses to influenza virus 
nucleoprotein (Tite et al., 1990). The  use of live attenuated Salmonella as carriers of foreign 
antigens has several attractive features. The organism is well-characterised and amenable to 
genetic manipulation. Potentially protective antigens from many pathogenic viruses and bacteria 
have been identified. These can be cloned and introduced into Salmonella, allowing the 
organism to express the protective antigens from several pathogens simultaneously. The  
resulting recombinant multivalent vaccine strain could be given orally, stimulating mucosal, 
humoral and cell-mediated responses. Thus one oral inoculation could, in theory, provide 
immunity to several different diseases.
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4.2 Materials and Methods
4.2.1 Gw-llnked ELISA on S. typhlmurtum lysates
G m, - linked ELISAs were performed on whole cell lysates of S. typhimurium SL1344 aroA ' 
aroD '  harbouring various constructs essentially as described previously (this thesis and 
Masked etal., 1987). Five O . D . , ^  units of an overnight culture were pelleted by centrifugation 
in an eppendorf tube. Th e  supernatant was removed and the tube carefully dried with 
absorbent paper. The tube was then knocked vigorously to loosen the pellet. Bacterial cell 
envelopes were disrupted by resuspending the pellet in 500pJ of 10%  (w/v) sarkosyl (sodium 
salt of N-lauroylsarcosine, obtained from Sigma, U .K.) and left at room temperature for 30-45 
minutes with occasional gentle agitation. 1 ml of L-broth was added to dilute the viscous solution 
and replicate 50pl aliquots were applied to a Gm,-coated 96 well microtitre plate. Th e  assay 
procedure was then as that followed for E. coli periplasmic fractions, described in Chapter 2.
4.2.2 Inoculation of mice
4.2.2.1 Preparation of bacterial Inocula for intravenous infection of mice
Single colonies of SL1344 a ro A '  aroD '  harbouring various constructs were inoculated into L- 
broth and grown statically overnight at 37°C. 1ml aliquots of these were then stored in liquid 
nitrogen. The next day, the viable count of this stock culture was determined by thawing an 
aliquot and diluting it in PBS to 10* and 10'7. 1 ml of the 10* and 2ml of the 10'7 dilutions were 
incorporated into triplicate samples of molten L-agar and used to pour plates. These were dried 
and incubated overnight at 37°C and the number of colony-forming units (cfu) determined.
W hen required to inoculate mice, an aliquot was thawed and diluted in PBS to 
approximately 1x107 cfu/ml and 1x10* cfu/ml. Mice were inoculated with 0.1-0.2ml of one of
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these suspensions into the tail vein. The  exact inoculum dose was determined by incorporating 
an aliquot of surplus inoculum into molten L-agar and counting as before.
4.2.2.2 Oral Inoculation of mice with S. typhlmurlum
T o  prepare inocula for oral infection of mice, frozen aliquots of stock cultures were used to 
inoculate 2 x 250ml bottles of L-broth which were incubated statically overnight at 37°C. Cells 
were harvested by centrifugation (~11,000g for 20 minutes) and the pellet resuspended in 4mls 
PBS. This procedure typically yielded a suspension with a count of ~5x1010 cfu/ml.
Oral inoculation was performed with a gavage tube: a blunt 2 inch, 18 gauge needle with 
a smoothed 2mm wide metal sheath over the end. Mice were lightly ether-anaesthetised and 
held by the skin between the eyes. They were allowed to swallow the needle which passed into 
the stomach. 200pJ of inoculum was administered from a 1ml syringe attached to the needle. 
Th e  exact dose delivered was determined as before by incorporating some of the inoculum into 
molten L-agar and performing a viable count.
4.2.3 Determination of growth curves In Infected mice
After inoculation with S. typhimurium, mice (generally four per group) were sacrificed at various 
time-points. Their spleens and livers were removed aseptically into separate sterile stomacher 
bags (Seward Medical Ltd.). 10mls of sterile distilled water were added to each bag and the 
organs homogenised for 3  minutes in a Colworth Stomacher. Serial tenfold dilutions of the 
homogenates were made in P B S. 1ml of these dilutions were incorporated into aliquots of 
molten L-agar, with and without ampidllin and used to pour plates. The  agar was allowed to 
set and the plates were then incubated overnight at 37°C. Alternatively, serial tenfold dilutions 
of the homogenates were made directly in 0.9ml aliquots of molten agar. Replicate 1OOpI drops
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of these dilutions were dispensed with a micropipette onto a Petri dish and allowed to set. The 
dishes were sealed with parafilm to prevent the drops from drying excessively. The next day 
colonies were counted with the aid of a colony counter. In this way, the total number of live S. 
typhimurium in these organs could be determined together with the proportion of those bacteria 
which retained the ampicillin resistant phenotype associated with carriage of the LT-B  fusion 
vector plasmids.
4.2.4 T  cell assays
The  generation of cytotoxic T  cells specific for the 110 and 114 epitopes in the corresponding 
L T -B  fusion proteins was investigated in mice which had been inoculated intravenously with 
SL1344 aroA '  aroD  " harbouring the appropriate constructs. At various times (generally 3-4 
weeks) after priming or boosting, 2 mice per group w ere sacrificed by cervical dislocation and 
their spleens removed aseptically into 10mls of sterile PBS. Single cell suspensions were 
prepared by gentle grinding between frosted glass slides. The  cells were washed twice in PBS 
and cultured (1-2 x107) in 10mls of Click's medium (supplemented with penicillin/streptomycin, 
L-glutamine and 0 .5%  normal mouse serum) together with normal spleen cells (5 x10*) or 
normal spleen cells which had been infected {in  vitro with allantoic fluid containing infectious 
influenza A/Puerto Rico/8/34 [PR8] virus) as stimulator cells. After incubation for five days (at 
37°C in an atmosphere of 5 %  C 0 2) the cultured cells were washed and serially diluted three 
fold. These dilutions were added to the wells of a 96 well U-bottomed microtitre plate (Costar). 
Appropriate target cells (either P815 or EL4 tumour cell lines) were radiolabelled by incubation 
at 37°C for 1 hour with 300pCi of 5,Cr-containing sodium chromate (Amersham, U.K.). The 
targets were then extensively washed and incubated for a further hour with 200 
haemagglutinating units (H A U ) of PR8 virus or 100pg of the relevant peptide (110 or 114). 
Control target cells were not exposed to antigen of any kind. A  constant number of target cells 
were added to the effector cells in the microtitre plate such that the maximum effectorrtarget
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ratio was about 20:1. The  plate was subjected to centrifugation (1,500 rpm for 5 minutes in a 
Sorvall RT6000B centrifuge) and incubated for 6 hours, after which time the culture supernatant 
w as harvested. The cytolytic activity of the cultured effector cells was measured by the amount 
of radiolabel released. Spontaneous release of radiolabel was determined by incubating 
labelled targets in isolation. Maximum release was achieved by lysing target cells with PBS 
containing 1% triton.
4 .3  Results
4.3.1 Expression of L T -B  fusion proteins In S . typhlmurium
N ovel plasmid constructs were introduced into the smooth strain of S. typhimurium, SL1344 
aroA  '  aroD  *, by means of the two-step transformation/transduction method described in 
sections 2.5.6.-7. Whole cell lysates were prepared (as described in 4.2.1) and analysed by 
G M1-linked ELISA, using LT-B-specific antiserum. Th e  results are shown in Figure 4.3.1.1. It 
w as found that L T -B  and the various L T -B  fusion proteins were expressed in S . typhimurium 
S L1 3 44  aroA '  aroD '  in a form capable of binding to G M1 and reacting with anti-LT-B 
antiserum. Similarly, when the monoclonal antibody BB05 was used as a probe in such assays, 
L T -B 6 9  expression could be detected in the strain carrying the appropriate plasmid (Figure 
4.3.1 .2). These findings are consistent with those described previously in Chapter 3. Moreover, 
an auxotrophic attenuated strain of S. typhimurium, SL3261, was shown previously to express 
L T -B  under the influence of the same P1 "anti-tet" promoter (Maskell at at, 1987). 
Nevertheless, these experiments were necessary to ascertain that expression of these 
molecules in a different host organism did occur and did not prevent the L T -B  fusion proteins 
from  binding to G «,.
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Figure 4.3.1.1 The G M1-binding activity of L T -B  and various L T -B  fusion proteins in whole cell 
lysates of S. typhimurium. Whole cell lysates were prepared from S. typhimurium SL1344 (the 
parental strain) and from strains harbouring plasmids directing the expression of L T -B  or LT-B  
fusion proteins. These w e re  probed in a GM,-linked ELISA with a polyclonal anti-LT-B antiserum. 
The results are shown in graphs A  and B above.
80
1.40
Figure 4.3.1.2 Detection of LT-B69 in a GM1-linked ELISA . Whole cell lysates were prepared from 
S. typhimurium SL1344 pFV1 and SL1344 pFV1 ::69. These were assayed in an E LISA  using the 
monoclonal antibody BB05 as a probe.
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One aim of this project was to express the L T -B  fusion proteins in attenuated strains of 
Salmonella, as Maskell e tai, (1987) had previously demonstrated that native L T -B  expressed from 
pBRD026 (i.e. expression driven by the same promoter at low-level) in S. typhlmurium SL3261 
could elicit systemic and secretory anti-LT-B antibody responses when given to mice orally.
An important characteristic of Salmonella spp. which allows them to act as efficient carriers of 
heterologous antigens (reviewed by Dougan & Tite, 1990) is the ability of the organism to persist 
in moderate numbers in the reticulo-endothelial system (R ES ) after infection of a suitable host 
(O'Callaghan et a/.. 1987). Unfortunately, under the strong selective pressures operating in vivo, 
plasmid stability in such strains is often poor (e.g. Tite et a i, 1990) once the bacteria are removed 
from the selective antibiotic present in in vitro cultures. Thus, before inoculating mice with S. 
typhlmurium S L 1 344 aroA '  a ro D '  harbouring the various fusion constructs, the stability of the 
plasmid in the bacterium in vitro, in the absence of ampicillin, was determined.
Single colonies from L-amp plates were inoculated into 3ml of L-broth without ampicillin. These 
were incubated at 37°C in an orbital shaker overnight. The next day, 30pJ of this culture were used 
to inoculate 3ml of fresh L-broth which was incubated overnight (again, at 37°C in a shaker). The 
remainder of the culture was diluted to 1/107 and 1/10* in PBS. Duplicate 2ml aliquots of each 
dilution were incorporated into samples of molten L-agar, with and without ampicillin. The colonies 
were counted the next day and the percentage of colonies retaining ampicillin-resistance was 
determined. Th is  process was repeated for the 2nd and 3rd passages. The results are shown 
below in Table 4.3.2. From these data it is apparent that after 3 passages, (representing a 
considerable num ber of bacterial generations, estimated to be about 20-30), all the plasmids are 
well maintained.
4.3.2 In vitro assay of stability of constructs In S. typhlmurlum SL1344 aroA' aroD'
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Table 4.3.2 The relative stability of LT-B fusion plasmids In vitro
Construct %  Stability after passage number
1 2 3
pBRD026 85 92 85
pFV1 54 54 46
pFV1::110 . 100 87 97
pFV1::167 32 23 20
pFV1::69 100 100 100
pFV1::114 81 73 79
The table shows the percentage of bacterial cells in the culture with an ampicillin-resistant 
phenotype after serial passage in vitro, an index of the percentage of cells retaining the L T -B  
fusion expression plasmids.
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4.3.3 In v iv o  evaluation of plasmid stability
In one such typical experiment, 30 C57BU6 mice were inoculated intravenously with about 10s cfu 
of SL1344 (pFV 1) or SL1344 (pFV1 ::114). Four mice per group were sacrificed at regular intervals 
and their livers and spleens removed aseptically into stomacher bags. The total number of 
Salmonellae in those organs, together with the number which remained ampicillin resistant, was 
determined (as described in 4.2.3). The results are shown in Figure 4.3.3.1. (graphs A  and B). 
Furthermore, the persistence in spleens and livers of S L1344 aroA '  aroD '  carrying these 
constructs appeared essentially unaltered from the behaviour of the parental strain (Dougan etal., 
1988), illustrated in Figure 4.3.3.2. Immediately after inoculation, there is a decline in the numbers 
of recoverable bacteria, presumably due to non-specific host-defence mechanisms. After a lag 
phase of about 24 hours, the inoculum enters a replicative phase. There is a net increase in 
bacterial count, peaking around days 10-14. By this point, specific immune mechanisms have 
become effective and the viable count slowly declines, the bacteria being finally cleared by about 
6-7 weeks post-infection. The graphs in Figure 4.3.3.1 show that both pFV1 and pFV1::114 are 
stable in vivo in the absence of antibiotic selective pressure, despite the lower stability of pFV1 
in in vitro assays.
However, in a similar experiment BALB/c mice were fed S . typhimurium SL1344 harbouring 
the plasmid pFV1 ::69. In contrast to the results obtained with SL1344 (pFV1 ::114), no ampicillin- 
resistant Salmonellae could be isolated from the livers or spleens of the mice by 3 weeks post­
infection (data not shown), despite pFV1::69 being maintained to a high degree in bacterial 
cultures in vitro (see Table 4.3.2). It would appear therefore that behaviour of the plasmid in 
bacterial cultures in vitro is not necessarily a good indicator of whether the plasmid is likely to 
segregate in a bacterial population in an animal host, at least in this model.
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Figure 4.3.3.1 The stability in vivo of plasmids pFVl and pFV1::114. Mice were inoculated 
intravenously with S. typhimurium harbouring the above plasmids. Mice were sacrificed at regular 
intervals and the number of viable Salmonellae In the liver and spleen was determined, together 
with the number of bacteria which retained ampicillin resistance. Points represent the mean group 
value (n-4), +/-1 SD.
85
Figure 4.3.3.2 The colonisation of the livers of Balb/c mice following i.v. infection with S. 
tyhpimurium aroA '  (• ) ,  S. tyhpimurium aroC '  (▲) and S. typhimurium aroA '  aroC'  (■). Each point 
represents the geometric mean ♦/- two standard errors (n-4). Reproduced from Dougan et a!., 
1988.
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4.3.4 Immunological evaluation following Inoculation with S . typhlmurlum harbouring L T -B  
fusion protein expression plasm ids
4.3.4.1 Serum antibody responses
The  immune responses of mice in the above experiment were investigated. Individual serum 
samples were taken from 4-5 mice per group and tested, by antigen-specific ELISA, for antibody 
to L T -B  and to the 114 epitope, corresponding to amino acid residues 364-382 of influenza A  virus 
nucleoprotein. As expected from the results of previous work (Maskell et at, 1987), mice in both 
groups mounted a detectable serum antibody response against L T -B  after priming. This was 
observed to increase slightly after the mice were given a second inoculation (see Figure 4.3.4, 
graph A). Mice in a control group inoculated with SL1344 alone did not develop serum anti-LT-B 
antibody. In addition, mice which were inoculated with SL1344 (pFV1::114) were found to mount 
a weak serum antibody response to the 114 peptide epitope (Figure 4.3.4, graph B). This was 
partially obscured by an increase in the background response. This was presumably due to a 
serological cross-reaction between the 114 peptide epitope and one or more Salmonella antigens 
as both the group inoculated with the parental strain and the group inoculated with SL1344 (pFV1) 
showed a similar increase in response after boosting. Mice inoculated with SL1344 am  A '  a ro D ' 
(pFVl::110) however, did not develop serum antibodies against peptide 110 (corresponding to 
amino acid residues 147-161 of influenza A  virus nucleoprotein), despite the persistence for 
several weeks of ampicillin-resistant bacteria in the infected mice (data not shown).
4.3.4.2 Cytotoxic T  lymphocyte responses
Unfortunately, a cytotoxic T  lymphocyte (C T L ) response to the C T L  epitope present in the 
sequence of peptide 114 could not be detected in C57BI/6 mice infected with S. typhimurium 
SL1344 aroA '  aroD  '  (pFV1::114), using either influenza A  virus (PR8) o r the corresponding
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synthetic peptide as the recall antigen. In contrast, in the same assays, spleen cells from mice 
which had been infected intravenously with PR8 virus contained a  population of cytotoxic T  cells 
which were reactive against either PR8-infected or peptide-pulsed target cells. In a  similar 
experiment, BALB/c mice inoculated with SL1344 aroA 'aroD '  (pFV1::110) failed to mount a 
detectable C T L  response to the peptide 110 epitope. Whilst there is uncertainty over the 
expression of LT-B110 (which could not be detected using 110-specific antisera in immunoblots 
or G M1-linked ELISA), no such doubt exists concerning the expression of LT-B114. Some 
speculations on the possible causes of this lack of T  cell reactivity to the 114 peptide epitope are 
discussed in the following section.
A A  B c
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Figure 4.3.4. The primary (day 28) and secondary (day 49) serum antibody responses to L T -B  
(top graphs) and peptide 114 (lower graphs) of mice immunised intravenously with (A ), S. 
typhimurium SL1344 (pFV1 ::114); (B), SL1344 (pFV 1) or (C ) SL1344 alone. The  mean values are 
represented by a horizontal bar (n -4  or 5).
4.4 Summary
A  number of reasons could be envisaged to explain the failure to detect heterologous epitope- 
specific T  cell responses In mice immunised with attenuated Salmonella. Firstly, the peptide 
sequence might well behave differently when fused to L T -B  than when present as an intrinsic part 
of influenza virus nucleoprotein. Thus nucleoprotein might be degraded by antigen-processing cells 
so as to yield the antigenic peptide fragment, peptide 114. However, the same amino acid 
sequence, when present in L T -B , might not generate the epitopic fragment. Similarly, it is possible 
that expression by Salmonella typhimurium may prevent the epitope being processed in the normal 
way. For instance, despite being essentially an intracellular parasite, (influenza virus similarly being 
an obligate intracellular parasite), the presence of bacterial antigens might lead to the preferential 
formation and/or recognition of other peptide fragments. Alternatively, a fragment might be formed 
which contains the epitope sequence but, because of its composition (i.e. incorporating LT-B  
sequences), is in a form unable to associate with the M HC  molecules of the H-26 haplotype.
A  second explanation could be that there are T  cell epitopes in L T -B  which are excessively 
immunodominant. Thus, even if the 114 epitopic fragment is formed and presented, the response 
of cytotoxic T  cells which recognise it might be masked or swamped by the response to other 
immunodominant epitopes. This could be easily tested by repeating the experiment and performing 
an assay for C T L  directed against LT-B .
This failure to detect C T L  responses to T  cell epitopes fused to L T -B  contrasts with the 
experience of SchOdel et at., (1990a,b). These workers constructed a plasmid vector directing the 
expression of one B cell epitope from hepatitis B  virus (H BV) pre-S(2) surface antigen (amino acid 
residues 133-140) and two overlapping T  cell epitopes from HBV core antigen (amino acid 
residues 120-140) fused to the C  terminal of L T -B . The  resulting fusion protein was expressed in 
an attenuated aroA '  strain of S. dublln SL1438, which was used to inoculate mice. After 3 oral 
doses splenic T  cells specific for the fused hepatitis B virus core antigen (H BVcAg) T  cell epitopes 
could be detected. Thus there are a number of differences between this previous work and the 
current study reported here, including route and number of inoculations, bacterial host strain and
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T  cell epitopes in the fusion protein. Furthermore, the above authors present no data concerning 
the G m,-binding activity of the fusion protein. This might be significant if, as outlined above, binding 
to Gy, alters the processing pathway followed by the antigen.
As described previously, the plasmid pFV1 ::69 was found to segregate in populations of S. 
typhimurium SL1344 aroA '  a r o D One possible solution to the problem of instability of plasmids 
expressing heterologous antigens in bacterial vectors is to integrate the relevant DNA, encoding 
the heterologous antigen, into the chromosome of the bacterial host. Chromosomal insertion 
vectors have been described w hich contain genes encoding heterologous potypetides flanked by 
sequences which are homologous to those of the host bacterium's chromosome. A  low frequency 
double crossover event allows homologous recombination to occur such that the heterologous 
antigen is then expressed from the chromosome. This approach has been used successfully to 
introduce sequences encoding tetanus toxin C  fragment into the chromosome of S. typhimurium 
(Strugnell at al„ 1990). The technique has the advantage of eliminating problems of plasmid 
instability. However, as there is only one chromosome per bacterial cell, levels of expression of 
the heterologous antigen are generally lower than those which can be achieved with high copy 
number expression plasmids.
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C H A P T E R  5
The partial purification of LT-B69
5.1 Introduction
An alternative to the use ot attenuated Salmonella spp. to achieve immunisation of mucosal 
surfaces is to directly inoculate mice orally or intranasally with purified proteins. Such an 
approach is feasible with L T -B  fusion proteins because of the properties of L T -B  discussed in 
Chapter 1. This chapter describes the purification of the LT-B69 fusion protein.
A number of methods have been described for purifying LT-B  and/or C T -B . One of the 
most efficient appears to be affinity chromatography, which utilises the G*,,-binding activity of 
the toxin B-subunits to retain them on a G u1-coated inert matrix (Tayot et a/., 1981). This 
technique has also been successfully employed to purify a C T-B  fusion protein (Dertzbaugh 
et a i, 1990).
In preliminary experiments, attempts to purify L T -B 6 9  from periplasmic fractions of E. coll 
HB101 (pFV1 ::69) by this method were unsuccessful. In view of the data showing that LT-B69 
retains G M1-binding activity, the most likely explanation for this is that the chemical derivatisation 
of the G m, (which involves reflux boiling for several hours with 10M Potassium hydroxide) did 
not occur correctly or that the lysoGM1 was not properly coupled to the inert matrix (Spherosil, 
Pharmacia).
L T  accumulates in the periplasm of E. coll w hereas V. cholerae will secrete both C T  and 
L T  into the extracellular milieu (Hirst et ai, 1988, Witholt et al., 1988). Thus if LT-B  fusion 
proteins can be expressed in an atoxigenic strain of V. cholerae (so as to avoid contamination 
by C T ),  they might be secreted into the medium, in the same way as the native toxin. This 
potentially simplifies purification into a process of concentration, as very little of other bacterial 
products are transported extracellularly from V. cholerae. (Indeed, one interesting question is
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what selective advantage is provided by cholera toxin secretion, in view ot the effort expended 
by the bacterium to export the toxin to the external medium? It may be that the symptoms of 
severe diarrhoea, which C T  induces, facilitate the spread of the organism). T h u s  one approach, 
described below, was the expression of pFV1 ::69 in an atoxigenic strain of V. cholerae, strain 
TRH 7000 (kindly provided by T. Hirst; Hirst et al., 1984b), the results of w hich are detailed in
5.3.
Ultimately, the method of choice used to purify LT-B69 was to separate the proteins from 
periplasmic extracts of HB101(pFV1::69) by means of ion-exchange chromatography. Whilst 
this did not achieve the high purity associated with affinity chromatographic techniques, it was 
simple to perform and did not require the use of low pH conditions (which might denature 
certain L T -B  fusion proteins) to dissociate LT-B69 from the column, which is necessary when 
using G,,,-affinity protocols.
5.2 Materials and Methods
5.2.1 Bacterial strains and plasmids
V. cholerae TRH7000 is an attenuated strain, being atoxigenic and auxotrophic for thymine, but 
is moderately resistant to polymixin B (PB). Typically, the strain was grown at 30°C on L-agar 
supplemented with thymine at 100 pg/ml and PB at 100 units/mi.
p F V l and p F V l ::69 have been described previously (this thesis). pR K2013 encodes all the 
tra gene functions from the broad-host-range plasmid RP4 and has been described previously 
(Figurski and Helinski, 1979). Thus in a tripartite mating involving E . coH HB101 
(pFV1)/(pFV1 ::69), HB101 (pRK2013) and V. cholerae TRH7000, pRK2013 can supply fra gene 
functions in trans, mobilising the pBR322-derived pFVl plasmids into the V. cholerae strain.
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5.2.2 Tripartite Bacterial Mating
E. coli cells containing the donor plasmids were scraped from a fresh L-amp plate to form a 
thick suspension in 0.5mls of L-broth. Similarly, a thick suspension was made of E. collHB101 
(pRK20l 3) cells. A  slightly less thick suspension was made of V. choleras TRH7000. Equal 
volumes (~100pl) of each suspension were mixed together and 50pl drops were put onto L- 
agar/thymine plates. These were incubated at 30°C for 2-6 hours to allow conjugation to 
proceed. The cells were then scraped from the plates into 0.5mls of L-broth. Serial tenfold 
dilutions of this suspension were made in L-broth and streaked out for single colonies on L- 
agar plates supplemented with thymine, PB and ampicillin (at 100pg/ml), (L -TP A  plates) to 
select for V. cholerae cells which had taken up the donor plasmids (encoding ampicillin- 
resistance). Plates were incubated for 24 hours at 30°C. The  resulting colonies were picked 
onto fresh L -T P A  plates and also onto L -TP A  plates supplemented with kanamycin at 50pg/ml. 
V. cholerae colonies which acquired the donor plasmids but which had lost the pRK2013 
"helper" plasmid (pRK2013 is unstable in V. cholerae) had the phenotype PBR, Amp” and Kms. 
Thus they will grow on L -T P A  plates but not on L -T P A  plates containing kanamycin. These 
colonies were screened for the expression of L T -B  and/or BB05 by the use of colony 
immunoblots. Positive-reacting colonies were streaked out on selective media and held at 4°C.
5.3 Results
5.3.1. Secretion of LT-BH and LT-B69 from V. cholerae TRH7000
The secretion of LT -B H  and LT-B69 from V. cholerae TRH 7000 was investigated by analysing 
cellular and extracellular fractions from cultures of V. cholerae (p F V l) and V. cholerae 
(pFV1 ::69) using a G ^-linked ELISA , as described in Chapter 2. The results are represented 
graphically in Figures 5.3.1.1-3.
Figure 5.3.1.1 shows that small amounts of L T -B H  can be detected in the culture
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supernatant after just 6 hours of culture. This is despite the fact that levels of expression in V. 
cholerae from the P1 "anti-tet" promoter are presumably no higher than in E. coli. This 
extracellular L T -B H  is unlikely to have been released from lysed or damaged cells as the 
amount of L T -B H  remaining cell-associated at this time-point is very small. Thus one can be 
reasonably confident that the protein reached the medium by active export rather than by a 
passive "leakage”. After 24 hours of culture there is much more cell-associated L T -B H  and very 
much more free LT -B H  in the medium: if one considers the relative values for the absorbance 
at the first dilution, the figure for the medium fraction is about 3 fold higher than that for the 
cellular fraction. This increase over time could be due to the stability of the protein resulting in 
a time-dependent accumulation and/or the greater cell density after a more prolonged period 
of culture.
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l o g 3 o f  r e c i p r o c a l  o f  d i l u t i o n
Figure 5.3.1.1 The secretion of L T -B H  from V. choterae was investigated by means of G*,,- 
linked ELISA . V. cholerae TRH 7000 p F V l was grown at 37°C in L-broth. At two time points (6 
hours and 24 hours after initaition of culture), 200pl of culture was sampled. The  cells were 
pelleted by centrifugation and disrupted by sonication in an equal volume of PBS. Aliquots of 
the cellular fractions prepared in this way, together with samples of the culture supernatant, 
were applied to a GM1-coated microtitre plate and probed with LT-B-specific antiserum in an 
ELISA.
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The situation appears slightly different with respect to the secretion of LT-B69, as illustrated 
by Figure 5.3.1.2. After 6 hours of culture, virtually all LT -B69  is still intracellular. After 24 hours 
however, the data are essentially as those obtained for L T -B H  in that there is far more LT-B69 
in the medium than remains cell-associated (again, with respect to the absorbance of the first 
dilution in the ELISA, the figure is about 3 times greater for the extracellular fraction than for 
the cellular fraction). The total amounts of Gy,-bound L T -B  epitopes, as judged by the sum of 
the absorbances for cellular and medium fractions, is essentially the same for L T -B H  and LT- 
B69 at both time-points. Thus it would seem that the presence of the BB05 epitope at the C - 
terminal of L T -B  does have some effect on the secretion of the protein from V. cholerae 
TRH7000 but does not affect the Gy,-binding properties of the molecule, relative to LT-BH. 
When the same assay was performed on cellular and medium fractions from cultures of V. 
cholerae TRH 7000 (pFV1 ::69), using the mAb BB05 as a probe, the results shown in Figure
5.3.1.3 were obtained. Surprisingly, at both 6 and 24 hours there was considerably more Gy,- 
binding BB05-specific epitope within the cellular fraction than in the medium, which appears 
contradictory to the presence of large amounts of L T -B  epitope in the medium after 24 hours, 
as shown by Figure 5.3.1.2. The probable explanation for this is that the BB05 epitope is being 
cleaved from the L T -B  moiety by a protease activity and so cannot be detected in a G M1-linked 
ELISA, (it is therefore not surprising that LT-B69 secreted from V. cholerae binds to G y, with 
an affinity comparable to that of L T -B H ). The fact that any intact extracellular LT-B69  can be 
detected implies that this proteolysis occurs very soon after, rather than before or during, export 
from the bacterial cell. This phenomenon has been experienced with other L T -B  fusion proteins 
secreted from V. cholerae (Schddel etal., 1991). In the light of these findings it was considered 
too difficult to attempt to purify LT-B 6 9  from cultures of V. cholerae (pFV1::69).
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Figure 5.3.1.2 Th e  secretion of LT-B69  from V. cholerae was investigated by means of G*,,- 
linked ELISA. Cellular and medium fractions were prepared (as described previously) from 
cultures of V. cholerae TRH7000 pFV1 ::69 at 6 and 24 hours after the initiation of culture. 
These samples were analysed in a G M1-linked ELISA, using LT-B-specific antiserum as a 
probe.
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l o g 3 o f  r e c i p r o c a l  o f  d i l u t i o n
Figure 5.3.1.3 The secretion of LT-B69 from V. choleras was investigated by means of a G M1- 
linked ELISA. Cellular and medium fractions were prepared (as described previously) from 
cultures of V. cholerae TRH7000 pFV1 ::69. These samples were analysed in a G M1-linked 
ELISA, using the monoclonal antibody BB05 as a probe.
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For the partial purification of LT-B69 fusion protein, large scale periplasmic fractions were 
made, as detailed in Chapter 2. from 2 litre batches of E. coli HB101 (pFV1::69) overnight 
cultures. These preparations were concentrated 20-25 fold using an Amicon Diaflo equipped 
with an XM50 membrane (Amicon Corporation. Maryland. USA ). Th e  reténtate was dialysed 
overnight against 50mM NaCI buffered to pH8.6 with 25mM Tris-HCl. The  dialysate was then 
loaded onto a DEAE Trisacryl column (Pharmacia, Sweden) equilibrated with the same buffer. 
After extensive washing (for about 1 hour) the bound protein was eluted with a 50-250mM NaCI 
gradient, buffered to pH8.6 as before. The A280nm of the eluate was continuously monitored with 
a UV-1 Single Path Monitor (Pharmacia) and a Servoscribe 210 recorder (Camlab, Cambridge, 
U K ). A  typical absorbance profile is shown in Figure 5.3.2. Fractions were collected and 
analysed by dot-blotting onto nitrocellulose and probing with the BB05 monoclonal antibody, 
followed by a mouse lg-specific rabbit antibody conjugated to horseradish peroxidase and 
developed with a suitable substrate. Positive-staining fractions were further analysed by S D S - 
P A G E . Those with the highest purity of LT-B69 were pooled. These pooled fractions were 
further concentrated 10-20 fold using Centricon 30 ultrafiltration tubes (Amicon), by 
centrifugation at ~6,000g for 30 minutes. The total protein content was determined using the 
Pierce B C A  microtitre assay. The material was then stored in 0.5ml aliquots and maintained 
at -20°C until required.
5.3.2 Partial purification of LT-B69 from periplasmlc fractions of E. coll
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Figure 5.3.2 A typical absorbance profile obtained during the partial purification of LT-B69 from 
concentrated periplasmic fractions of E. coli HB101 pFV1 ::69. About 5 0 %  of the protein in the 
extract did not bind to the Trisacryl column and passed straight through. After washing for ~1hr 
in 50mM NaCI/25mM Tris -H C I pH8.6, a 50-250mM NaCI gradient (at the same pH) was 
applied. The  LT-B69-containing fractions (arrowed) were eluted towards the end of the run.
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5.3.3 Characterisation of partially purified LT-B69
The purification was monitored by analysing samples before and after purification by means 
of S D S -P A G E , as shown in Figure 5.3.3.1. Clearly, the pooled fractions are by no means pure. 
There are several contaminating proteins, the main contaminant running with an apparent M, 
of ~29kDa. However, there is considerable enrichment for LT-B69, of which none appears to 
be lost by passing straight through the ion-exchange column (as judged by S D S -P A G E ). It is 
apparent that some degradation takes place during the purification. In the unboiled sample 
there are 2 well-represented bands with apparent M, values of ~68kDa and 90kDa and a fainter 
band which migrates with an apparent M, of 97kDa, which presumably represent variously 
degraded forms of the fusion protein. All three bands have indistinct margins, implying 
breakdown products with a  range of molecular weights rather than a few discrete forms of L T - 
B69. Upon boiling, all of these multimeric forms of LT-B69 disappear and a single, sharply- 
defined, new band, corresponding to monomeric LT-B69, is formed at a position equating to 
an M, of 18kDa. Thus, with respect to pentamer formation and dissociation into monomers upon 
boiling, the partially purified fusion protein behaves identically to LT-B69 in crude E. coli 
periplasmic fractions.
It was clearly important to ensure that as well as forming pentameric complexes the partially 
purified protein could stilll bind to G M1. Thus the affinity for G M1 of the partially purified material 
was compared with crude E . coli periplasmic fractions containing LT-B69 by means of a G*,,- 
linked ELISA.
102
97 —  
69 —
► •
46 —  ~
30 — ___________
21 . 5 —  ►  _
14 . 3 —
1 2 3 4
Figure 5.3.3.1 S D S-P AG E analysis of periplasmic fractions from E. coli HB101 pFV1::69, 
before and after purification of LT-B69. Lane 1, total periplasmic protein from HB101 pFV1 ::69, 
as loaded onto DEAE Trisacryl column; lane 2. unbound proteins which flowed straight through 
the column, lane 3, pooled LT-B69-containing fractions eluted from the column (unboiled); lane 
4, pooled LT-B69-containing fractions eluted from the column (boiled). Bands containing L T - 
B69 are arrowed. Relative molecular mass markers (in kiloDaltons) are shown on the left.
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Purified preparations of LT-B69 were diluted in PBS so as to give 1/10 and 1/20 of the total 
protein content of an E. coti (pFV1::69) periplasmic fraction, and applied to a G*,-coated 
microtitre plate. The results are shown in Figure 5.3.3.2. From this one can conclude that the 
purification process does not abolish the G^-binding properties of L T -B 6 9 . Furthermore, the 
graph suggests that the purification achieves an enrichment of LT-B6 9  of between 10 and 20 
fold, the actual figure lying towards the upper limit of that margin.
It is generally believed that monomeric L T -B  has only a very low affinity for G*,, (IkJa et al., 
1989, Sixma et al., 1991). Whilst this is a reasonable assumption, it is difficult to find much 
evidence for it in the literature. For this reason, the Gut-binding properties of LT-B69 were 
further investigated by G M1-linked ELISA, using either unheated partially purified LT-B69 or an 
equal amount of the same preparation which had been subjected to boiling for 10 minutes. The 
samples were then probed with the BB05 mAb. This was the probe of choice because some 
of the epitopes of C T-B  are thought to be conformational and heat-labile (D avid Lewis, personal 
communication). By contrast, the BB05 mAb recognises a linear sequence and will bind to 
denatured LT-B69 very efficently in an immunoblot. The results are shown below in Figure
5.3.3.3. It was found that boiling LT-B69 does prevent the fusion protein from binding to G*,,. 
Unfortunately, this does not provide direct evidence that the monomeric nature of boiled LT-B69 
is responsible: an equally valid explanation is that boiling causes unfolding of the LT-B  
polypeptides and that this denaturation destroys the conformation necessary for Gy,-binding 
activity. This problem is a difficult one to overcome because it requires obtaining monomeric 
L T -B  in a  native form, yet monomers of L T -B  associate very readily into pentamers.
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l o g 3 o f  r e c i p r o c a l  o f  d i l u t i o n
Figu re  S.3.3.2 The G M,-binding activity of LT-B69 is preserved during the purification process. 
Samples of partially purified LT-B69 were adjusted to a concentration of total protein of 4ng/ml 
or 8pg/ml. A crude periplasmic extract was prepared from E. coliHB101 pFVl ::69 and adjusted 
to a concentration of total protein of 80pg/ml. The GM1-binding activity of these samples was 
then compared in a G M1-linked ELISA, using the monoclonal antibody BB05 as a probe.
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l o g 3 o f  r e c i p r o c a l  o f  d i l u t i o n
Figure S.3.3.3 The  G M1-binding activity of boiled and unboiled partially purified LT-B69. Equal 
concentrations of partially purified LT-B69 were applied, either boiled or unheated, to a G ^ -  
coated microtitre plate and probed with the monoclonal antibody BB05.
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5.4 S um m ary
The  transport of L T  and L T -B  in E. coli and V. cholerae has been studied quite extensively. 
Witholt at al., (1988) established that when expressed in E . coli, L T -B  is released into the 
periplasm as early as 13-14 seconds after the initiation of synthesis. Within that period, the 
nascent polypeptide is transported to and across the cytoplasmic membrane, during which 
process the 21 residue N-terminal signal sequence is proteolytically cleaved. Once released 
into the periplasmic space, the polypeptide is oxidised, allowing a disulphide bridge to form 
between residues 9 and 86 (Sixma at al., 1991). The  final processing step is the formation of 
B-subunit pentamers and, in the presence of L T -A , holotoxin.
Processing of L T  in V. cholerae is broadly similar, with cleavage of the signal sequence 
peptide during transit across the cytoplasmic membrane. The  B-subunit monomers then 
transiently enter the periplasm prior to oligomer and holotoxin formation (Hirst & Holmgren, 
1987a). T h e  major difference is that once assembled in the periplasm of V. cholerae, L T  or 
pentameric L T -B  are then further transported across the outer membrane into the extracellular 
medium. Th u s  V. cholerae must possess at least one extra pathway, which is absent in E. coli, 
which is necessary to facilitate secretion. Secretion of L T -B  can occur in the absence of LT-A. 
The reverse however is not true (Hirst etal., 1984b). This suggests there must be information 
inherent in L T -B  (and C T -B ) which is preserved in the two recombinant proteins LT-BH  and LT- 
B69. This final step in the pathway is extremely interesting as it appears that toxin secretion 
involves translocation of the molecule in a folded, stable quaternary structure. Transport of a 
large protein across the outer membrane would seem to represent a considerable problem to 
the bacterium. Quite how this is brought about in V. cholerae is unclear. Perhaps a B-subunit- 
specific protein in the outer membrane recognises the protein and facilitates the process.
Experiments were performed which suggested that possible degradation of LT-B69 
occurred when the protein was expressed in V. cholerae. These  findings are in agreement with 
the experience of Schbdel et al., (1991) who found that, whilst one fusion between L T -B  and 
sequences from hepatitis B virus (HBV) middle surface antigen was secreted into the
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supernatant of V. cholerae cultures, two similar L T -B  fusion proteins were retained 
intracellularly or rapidly degraded once they became extracellular. For this reason other 
methods of purification were selected. However, in the longer term there are a number of 
possible ways of overcoming this problem. For instance, it might be possible to construct a 
strain of V. cholerae lacking the protease(s) involved, if the gene(s) responsible were identified. 
Alternatively, the kinetics of expression of the protease(s) and LT-B69 might be different (only 
2 time-points were investigated). Thus at some point during the culture it might be possible to 
isolate undegraded LT-B69 from the culture supernatant.
With regard to the actual protocol used to purify LT-B69 from E. coli periplasmic fractions, 
the technique was clearly not ideal as LT-B69 represented only about 38%  of the total protein 
in the final sample. However, the concentration of LT-B69 in the starting material was low (~2% 
of total protein), thus the process achieved approximately a 17 fold enrichment (which agrees 
with the data obtained from GM,-linked ELISAs performed on crude and partially purified 
material). If the basic fusion vector (pFV1) was re-designed (e g. so as to utilise a  stronger 
promoter) such that higher levels of expression resulted, the purification of the associated 
fusion proteins would be greatly facilitated.
The  incorporation of further purification steps could probably increase the purity of LT-B69. 
However, this might well cause greater degradation than was observed with the relatively 
simple purification protocol employed. The degree of degradation is of importance because any 
diminution of Gg,-binding by the L T -B  moiety, or separation of the fused epitope from LT-B, 
could reduce the immunogenicity of the heterologous epitope, whereas for the requirements 
of intranasal immunisation experiments (described in the following chapter), the absolute purity 
of the preparation was of less significance.
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C H A P T E R  6
Immunisation with partially purified LT-B69
6.1 Introduction
Having obtained partially purified LT-B69 in a pentameric form able to bind G y „ as described 
in the preceding chapter, it was obviously desirable to investigate the immunogenicity of the 
fusion protein. Rather than attempting to inoculate mice by the more conventional routes (i.e. 
sub-cutaneously or intramuscularly), it was decided to inoculate mice intranasally. The rationale 
for this approach was as follows; firstly, the rationale of the project was the considerable 
immunogenicity of L T -B  when applied to mucosal surfaces (far greater than that of 
"conventional" immunogens, such as KLH). As discussed in Chapter 1, the greater T  helper 
cell:T suppressor/cytotoxic cell ratio of bronchus-associated lymphoid tissue (compared to gut 
associated lymphoid tissue), amongst other reasons, might make the conditions for obtaining 
an antibody response more favourable in the respiratory tract than in the gut. Secondly, B. 
pertussis is a pathogen of the respiratory tract, thus any local response to the BB05 epitope 
in the respiratory tract might be of considerable significance: there is some evidence to suggest 
that the current parenterally inoculated vaccine protects against the disease, that is. the 
symptoms of pertussis (for example by generating an anti-toxin serum antibody response), but 
does not protect against infection. Thus the current vaccine does little to prevent transmission 
of the causative organism. A third consideration is that very little research has been published 
regarding the immune response to C T -B  or LT-B  following intranasal inoculation, the work of 
Bessen & Fischetti (1988, 1990), Tamura and his co-workers (Tam ura et al., 1988, 1989) and 
Takahashi et al., (1991) being the main exceptions.
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6.2 Materials and Methods
Aerosol Infection of mice with B. pertussis
Stock cultures of B. pertussis, stored in liquid nitrogen, were thawed and spread onto C W  blood 
agar plates containing streptomycin. These were incubated for 3-4 days. The  bacteria were 
then transferred into PBS using sterile dacron swabs (Baxter Healthcare Corporation, Illinois, 
U S A ). Th e  O .D -uo ^ of the resulting suspension was adjusted to -0 .55. This corresponds to a 
count of ~4 x 10® cells/ml. An aerosol was created from this suspension, using a CR60 high 
flow nebuliser (Medic-Aid, Pagham, Sussex, UK). The  nebuliser was equipped with a System 
22 "turret turbo" (Medic-Aid) which, according to the manufacturer's specifications, generated 
an aerosol in which 85%  of the particles were less than 5.27pm in diameter (with an absolute 
minimum size of 2.3pm diameter). Mice which had been previously inoculated with LT-B69  
fusion protein or control preparations were exposed to this aerosol for 30 minutes, exactly as 
described by Roberts eta/., 1990. Immediately afterwards some animals were sacrificed and 
viable counts performed on homogenates of their lungs to determine the size of the inoculum 
which had seeded in the lower respiratory tract. Aerosol infection of mice using this technique 
has been shown to produce a fairly uniform degree of initial colonisation (Sato et al., 1980) and 
has been adopted by a number of researchers (Novotny etai., 1985, Shahin e ta i,  1990b, and 
Kimura et al., 1990).
6.3 Results
6.3.1 Preliminary experiment Involving Intranasal Immunisation with partially 
purified LT-B69
G roups of 5 BALB/c mice were lightly ether-anaesthetised and primed intranasally with 20pg 
of L T -B  or LT-B69 in a volume of 40pl of PBS. The inoculum was dispensed in 2-3 drops from
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a micropipette into the nostrils. The mice were boosted 4 weeks later with the same dose of 
antigen and by the same route. Serum  samples were taken at various time points and either 
pooled or analysed individually, the titres of LT-B-specific and P.69-specific antibody being 
determined by means of an antigen-specific ELISA, as described in 2.10.1. Titres were defined 
as the reciprocal of the dilution of serum giving half the maximal absorbance at 450nm. The 
results are shown in Figures 6.3.1.1 and 6.3.1.2.
Figure 6.3.1.1 shows that high titres of anti-LT-B serum antibody developed in mice 
inoculated with either LT-B  or LT-B69. The primary response appeared to be slower in mice 
which received the LT-B69 fusion protein. However, after boosting the anti-LT-B titres were 
essentially the same in both groups. From this it is clear that the BB05 epitope had little, if any, 
effect on the immunogenicity of the L T -B  moiety. Figure 6.3.1.2 shows that P.69-specific serum 
antibody could be detected in mice immunised intranasally with LT-B69 but not in the control 
group. The kinetics of this anti-P.69 response were those of a typical low level primary 
response followed after boosting by a more rapid secondary response attaining a higher titre.
I l l
Figure 6.3.1.1 Serum antibody response ot mice immunised with L T -B  or LT-B69. BALB/c mice 
were immunised intranasally with 20pg ot LT-B  (O ) or LT-B69 (□ ) and boosted 4 weeks later 
by the same route. Pooled or individual serum samples were obtained on the days shown. Anti- 
L T -B  litres were determined by antigen-specific ELISA and represent the reciprocal of the 
serum dilution giving halt maximal absorbance. Where sera were assayed individually, the 
points represent the mean values (n-5), +/- 1 S.D.
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2.2
Figure 6.3.1.2 Serum antibody response of mice immunised intranasally with LT-B (O ) or LT- 
B69 (□ ). Anti-P.69 litres were determined, as described previously, for serum samples obtained 
on the days shown. Where sera were assayed individually, the points represent the mean 
values (n-5). +/- 1 S.D.
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Three weeks after boosting the mice were sacrificed and EL IS P O T assays w ere performed on 
homogenates of their lungs as described in 2.10.2. LT-B-specific A S C  were detected in both 
groups of mice, as shown in Figure 6.3.1.3. These were either of the IgG o r IgA isotypes. No 
LT-B-specific IgM-secreting cells were detected. This was not surprising as the assay was 
measuring a secondary response, thus one would expect a certain degree of maturation of the 
response and concomitant antibody class-switching. A  low number of P.69-specific A S C  were 
detected in mice immunised with LT-B69 (Figure 6.3.1.4), but not in the control group. These 
P.69-specific A S C  were mostly of the IgG isotype but some IgM-secreting cells were also 
found. This might reflect a true difference in the immunogenicity of the BB05 epitope compared 
to LT-B  but it is more probably a distortion due to the low number of A S C  detected. 
Subsequent experiments showed that the lung immune response to P.69 was essentially of the 
IgG and IgA isotypes, like the response to LT -B .
These results were extremely encouraging. Although the serum antibody titres specific for 
P.69 were quite low compared to the anti-LT-B  titres. the detection of a  serum antibody 
response to P.69, following intranasal immunisation with LT-B69, was very significant. Mice 
inoculated intranasally with two doses (each of 10pg) of purified P.69 developed P.69-specific 
A S C  in their lungs but failed to mount an anti-P.69 serum antibody response (M. Roberts, 
unpublished observation). Thus coupling of the BB05 epitope to L T -B  was shown to enhance 
the immunogenicity of the heterologous epitope, at least with regard to serum antibody 
responses.
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Figure 6.3.1.3 A nti-L T-B  antibody-secreting cells (ASC) in the lungs of intranasally immunised 
mice. BALB/c m ice were inoculated with L T -B  or LT-B69 as described previously. Three weeks 
after boosting, lymphocytes were isolated from the lungs and antigen-specific, isotype-specific 
ELI S P O T  assays were performed to enumerate the LT-B-specific A SC . The antigen-specificity 
of the assay w as demonstrated by the lack of reactivity in the control wells containing medium 
without antigen.
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Figure 6.3.1.4 P.69-specific antibody-secreting cells (ASC) in the lungs of mice immunised 
intranasally with L T -B  or LT-B69. E L IS P O T  assays were performed as described previously.
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6.3.2 Immunisation schedules for aerosol challenge experiment
Eight groups of mice (10 BALB/c males per group) were primed on day 0 (and boosted 3 
weeks later) with the antigen(s) and by the routes shown in Table 6.3.2.1 below, prior to 
challenge with an aerosol of B. pertussis, as described in 6.2.
Most groups were inoculated intranasally so as to study further the immunogenicity of LT- 
B69 when applied to mucosal surfaces. As a comparison, two groups were inoculated 
intramuscularly. The contrasting routes of inoculation might also have yielded information 
regarding the mechanism of protection (if any) against colonisation by B. pertussis, following 
an aerosol challenge. Another group included for comparison w as inoculated with a  synthetic 
peptide (peptide 683, see Figure 6.3.2.1 and Charles et al., 1991, synthesised by D. Cambell, 
Wellcome Research Laboratories), corresponding to the B B 05 epitope sequence, linked 
covalently to the carrier molecule K LH  (which is not a mucosal adjuvant). Two methods of 
potentially enhancing the immune response to LT-B69 were also investigated. One method 
involved the incorporation of a small amount of C T  (0.1 pg) into the inoculum, which has been 
demonstrated to be an effective mucosal adjuvant when given to mice orally (Elson & Ealding, 
1984a) or intranasally (Tamura et al., 1989). The other method selected involved treating mice 
intranasally. 2-3 hours prior to immunisation, with 1 mg of G*,, (Sigma) in drops with a total 
volume of 40pl. Such a protocol has been used successfully to increase the immune response 
of mice immunised intranasally with particulate antigens containing C T-B  (Martin Ford, 
Wellcome Research Laboratories, personal communication). It is assumed that enhancement 
of the immune response occurs because exogenous G WI is taken up by the epithelial cells 
lining the respiratory tract, thereby increasing the concentration of ganglioside on the epithelial 
surface. This in turn facilitates the subsequent binding of molecules with an affinity for G*,, 
(such as LT-B ).
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Table 6.3.2.1. Immunisation protocols used for mice In a B. pertussis aerosol challenge
experiment
Group Immunisation schedule
1 20pg LT-B 6 9 1, intramuscularly (i.m.)
2 20pg LT-B69 plus 0.1pg C T , i.m.
3 20pg LT-B69, intranasally (i.n.) |
4 1 mg G m, i.n. pre-treatment, then 20pg LT-B69  i.n.
5 20pg LT-B69 plus O .lpg C T , i.n.
6 im g G m, i.n., then 20pg LT-B69 plus 0.1pg C T  i.n.
7 20pg peptide 683/KLH conjugate2, i.n.
8 20pg irrelevant protein3 plus 0.1 pg C T , i.n.
\  this figure represents the amount of LT-B69 in the inoculum; as the fusion protein constituted 
about 1/3 of the total protein, the amount of total protein in the inoculum was ~60ng.
2, an amount sufficient to contain 20pg of peptide, (rather than 20pg of conjugate), w as used.
3, this irrelevant protein consisted of E. coli periplasmic proteins collected during the partial 
purification of LT-B69. This material did not bind to the Trisacryl column used in the purification 
and so passed straight through. The protein content was assayed by the Pierce method, 
adjusted to 0.5 mg/ml and stored in aliquots at -20°C.
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Figu re  6.3.2.1 The  amino acid sequence of P.69 in the region of the BB05-binding epitope, 
showing the precise sequence of peptide 683, which was conjugated to KLH and used as a 
control immunogen in the intranasal immunisation experiments. Th e  numbers refer to the amino 
acid residues of the mature (i.e. signal peptide-processed) form of P.69. The L T -B  fusion differs 
from the B. pertussis sequence at position 567 (pro-»asp) and peptide 683 differs at position 
574, having a carboxy terminal cysteine to facilitate coupling to carrier molecules.
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Figure 6.3.2.2 shows a sample of the material used as the LT-B69  inoculum (compare Figure 
5.3.3.1). This gel was subjected to further analysis by means of a densitometer. The  plots of 
the unheated and the boiled samples are shown in Figures 6.3.2.3 and 6.3.2.4. The  peaks 
representing pentameric and monomeric LT-B69 are arrowed. Figure 6.3.2.3 shows three 
peaks (constituting 34 .8%  of the total absorbance of the track) in the unheated sample, which 
are absent from the boiled sample. These represent pentameric LT-B69 and two slightly 
degraded breakdown products. Figure 6.3.2.4 illustrates the presence of a new peak in the 
boiled sample, corresponding to monomeric LT-B69, constituting 38.4%  of the total absorbance 
of the track (i.e. about the same as the sum  of the three bands in the unheated sample). Using 
these data, in conjunction with the results of a an assay of the total protein concentration of the 
sample, it was possible to determine the dose (in pg) given to the mice.
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Figure 6.3.2.2 S D S -P A G E  analysis of LT-B69 partially purified from periplasmic fractions of E. 
coll HB101 pFV1::69. This material was used to inoculate mice intranasally prior to aerosol 
challenge with B. pertussis. Lane 1, relative molecular mass standards (with mass shown in 
kiloDaltons on the left); lane 2, partially purified LT-B69 inoculum (unboiled); lane 3, partially 
purified LT-B69 inoculum (boiled). Bands containing LT-B69 are arrowed.
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Figures 6.3.2.3-4 Densitometry analysis of lanes 2 (top) and 3 (above) of the gel shown in 
Figure 6.3.2.2. Peaks 1-3 represent pentameric LT-B 6 9  and its associated breakdown products. 
Peak 4 represents monomeric LT-B69.
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6.3.3 Aerosol challenge ELISP O T data
Table 6.3.3 (below) shows the number of LT-B-specific antibody secreting cells (A S C ) in lungs 
of mice 7 days after boosting intramuscularly or intranasally with LT-B69.
These tables contain a great deal of data which require careful analysis. Firstly, a number 
of points should be raised concerning their interpretation. The assays were not standardised. 
The IgG-specific conjugate might have had a rather higher affinity than the IgA-specific 
conjugate, or vice versa. Thus direct comparisons of cell numbers secreting antibody of 
different isotype are not strictly valid, so where such differences are small, speculation is 
dangerous.
Secondly, some of the groups received antigen adjuvanted with cholera holotoxin. Even 
though the mass of C T  given (0.lpg) was very small compared to the antigen dose (20pg), 
representing less than 1 %  of the total protein in the inoculum, because of the serological cross­
reactivity between C T  and LT-B, there is the probability that not all of the LT-B-specific ASC  
detected in these assays were truly directed against LT -B . It is evident from the results 
obtained from group 8 (which received irrelevant antigen together with C T ) that this effect is 
not major but does contribute to the total number of A S C  detected.
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Table 6.3.3 The number of LT-B-specIfc A S C  In the lungs of mice Inoculated Intranasally
or Intramuscularly with LT-B69
Group ASC /10* lymphocytes
IgG IgA IgM
1 N.D. N.D. N.D.
2 N.D. N.D. N.D.
3 2.4 x 103 2.1 X 10" N.D.
4 3 .8  x 103 7 .4  x 103 0 .3  X 10*
5 9.4 x 103 1 .4  x  104 0 .3  X 10s
6 2 .2  x  104 8 .6  X 10’ 0 .9  X 10*
7 0 .9  x 101 N.D. N.D.
8 0 .3  x  103 1.6 x 103 N.D.
(N.D. -  not detected)
No P.69-specific AS C  were detected except in groups 5 and 6. shown below 
(number/108 lymphocytes):
Group IgG IgA
5 2 5
6 1 3
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Another observation which can be made concerning the number of LT-B-specific A S C  in the 
lungs of mice in group 8 is that the inclusion of C T  in the inoculum appears to 
disproportionately enhance the IgA response. Thus there are about 8 fold more LT-B-specific 
IgG-secreting cells in the lungs of mice from group 3 (which received no C T ) compared to 
those of group 8 (which did receive C T ), whereas for A S C  of the IgA isotype the difference is 
only 1.3 fold. A  similar comparison can be made between groups 3 and 5, where mice in group 
5 were immunised by the same route with exactly the same inoculum (save the incorporation 
of C T )  as mice in group 3. Th e  increase in number of IgG-secreting cells was 3.9 fold whilst 
the magnitude of the IgA response was increased ~6.5 times. This observation is in agreement 
with the results of Chen & Strober (1990) who found that oral administration of C T  could 
disproportionately augment the IgA response to co-administered influenza virus.
Bearing in mind the previously stated caveat concerning comparisons involving absolute 
numbers of A S C  of different isotypes it is none the less apparent that, in all groups, A S C  of the 
IgM isotype were either not found or were present only in very small numbers. This is not 
surprising. The assay was investigating a secondary response, thus one would expect a certain 
degree of maturation of the response, concomitant with class-switching. Equally, the 
preponderance of IgA- and IgG-producing cells, and their approximate equivalence in number, 
is in agreement with the findings of Brandtzaeg (1988), concerning the distribution of IgA-, IgG- 
and IgM-secreting cells in the normal lower respiratory tract of humans.
Another observation which can readily be made is the complete lack of antigen-specific 
A S C  in the lungs of those mice inoculated intramuscularly. These mice did mount a systemic 
response, as evidenced by their serum antibody titres (see Figures 6.3.4.1. and 6.3.4.2). This 
is evidence that the lung E L IS P O T assay is a true index of a local response and that there was 
no significant contamination of the samples by, for example, peripheral blood lymphocytes (the 
mice having been exsanguinated prior to removal of the lungs).
Clearly, the number of LT-B-specific A S C  in the lungs of immunised mice is far higher than 
that of P.69-specific A S C . This is probably due to the greater number of B cell epitopes in L T -B  
and the cross-reactivity of L T -B  with C T . Even so, it is somewhat surprising, considering the
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results obtained from the preliminary experiment, in which small numbers of P.69-specific A S C  
were elicited without the need for C T  adjuvant (Figure 6.3.1.4). This is possibly due to a greater 
degree of degradation in the fusion protein inoculum, observed by S D S-PAG E, leading to a 
loss of G*,,-binding activity by the L T -B  pentamer and to cleavage and/or degradation of the 
BB05 epitope. This low number of anti-P.69 A S C  is reflected in the non-appearance of anti- 
P.69 slgA in the lung washes of intranasally immunised animals (data not shown). 
Nevertheless, it is significant that intranasal inoculation of peptide 683, corresponding to amino 
acid residues 544-574 of the mature P.69 sequence, failed to elicit either P.69-specific A S C  
or P.69-specific serum antibody (see Figure 6.3.4.2, below).
6.3.4 Antigen-specific serum antibody levels
6.3.4.1 A n tl-LT -B  serum antibody levels
An increase in the levels of anti-LT-B serum antibody could be detected in all groups which 
received the LT-B69 fusion protein, whether the route of administration was intramuscular or 
intranasal (see Figure 6.3.4.1). This increase was only slight after priming but after boosting 
significant increases were observed with the peak response generally occurring 1 -2 weeks after 
boosting. Neither group 7 (immunised with a peptide from P.69) nor group 8 (immunised with 
an irrelevant E. coli protein preparation) displayed substantially increased LT-B-specific serum 
antibody levels, although some mice in group 8 showed a small response to the C T  adjuvant. 
The presence of C T  in the inoculum caused a marked enhancement of the anti-LT-B antibody 
response, irrespective of the route of inoculation, bringing about a 2 fold increase in the mean 
absorbance in ELISAs. By contrast, pre-treatment of mice with intranasally applied Gy, had 
little, if any effect on L T -B  specific antibody levels. These results are broadly in line with the 
lung ELISP O T data in that groups 5 and 6 both had the highest number of LT-B-specific A S C  
in the lung and both had the greatest amount of circulating antibody.
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Figure 6.3.4.1 The  LT-B-specific serum antibody response following immunisation with LT-B69, 
with or without various adjuvants (see Table 6.3.2.1). Individual serum samples were obtained 
on the days shown, diluted 1/1000 and analysed by ELISA. Mean values for each time point 
are represented by a horizontal bar.
6.3.4.2 Antl-P.69 serum antibody levels
A  number of general points can be made concerning the levels of P.69-specific serum antibody 
in the mice (shown in Figure 6.3.4.2). Firstly, the background levels of absorbance in the ELISA 
assays was inexplicably high for all groups, despite the use of specific pathogen-free mice 
(uninfected by B. bronchiseptica). Secondly, the overall amount of P.69-specific antibody was 
considerably lower than that for L T -B . This may be explained by recent epitope-mapping 
experiments (Charles etal., 1991) with P.69, which suggest that the sequence of P.69 inserted 
as a fusion with L T -B  contains a single epitope -  that recognised by the monoclonal antibody 
BB05. Thirdly, there was no enhancement of anti-P.69 serum antibody levels following 
challenge with B. pertussis, despite the exposure to large amounts of P.69 that such a 
challenge would involve. This is not surprising. The region of P.69 present in LT-B69 does not 
contain any T  helper cell epitopes (J . Tite and M. Roberts, personal communication). Thus 
immunisation with LT-B69 would not generate any memory T  helper cells specific for P.69. 
Therefore, even in challenged mice which had been inoculated with LT-B69, P.69-specific A S C  
received T  cell help as a primary response.
Mice in group 8, which received irrelevant protein, failed to mount an anti-P.69 response. 
Mice in group 7, which received the P.69 peptide intranasally, appeared to mount a very slight 
response, as did groups 1 and 3, which were immunised with unadjuvanted LT-B69 fusion 
protein intramuscularly and intranasally respectively.
As with the anti-LT-B response, inclusion of small amounts of C T  in the inoculum 
significantly enhanced the amount of anti-P.69 serum antibody, whether given intramuscularty 
(group 2) or intranasally (group 5). This is confirmation of the adjuvanticity of C T ;  interpretation 
of the results is facilitated by the lack of serological cross-reactivity between C T  and P.69, 
unlike C T  and LT-B.
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q69K
Figure 6.3.4.2 The  P.69-specific serum antibody response following immunisation with LT-B69, 
with or without various adjuvants. Individual serum samples were obtained on the days shown, 
diluted 1/540 and analysed by means of an ELISA. Mean values for each time point are 
represented by a horizontal bar.
Pre-treatment of mice with Gy, appears to have a more significant effect on anti-P.69 titres than 
anti-LT-B  titres, although the situation where both G y, pre-treatment and C T  adjuvant were 
used (group 6) appears to dampen the response relative to C T  adjuvant alone (illustrated to 
a lesser extent by the anti-LT-B serum antibody levels). It may well be that insufficient time was 
allowed between the administration of Gy, and the inoculum, allowing exogenous unbound 
ganglioside to adsorb part of the inoculum.
Th e  detection of P.69-specific A S C  in the lung and P.69-specific serum antibody illustrates 
the successful use of an L T -B  chimeric protein to stimulate both local and systemic immune 
responses to a genetically fused epitope delivered intranasally. This finding is significant 
because intranasal immunisation of mice with recombinant P.69 purified from E. coli or native 
P.69 purified from B. pertussis fails to stimulate serum anti-P.69 antibody (M. Roberts, personal 
communication).
6.3.5 Viable B. pertussis counts In lungs of infected mice
Seven days after boosting, all the mice were challenged with an aerosol of B. pertussis, as 
described in Chapter 2. Immediately after exposure to the aerosol, 4 unimmunised indicator 
mice were sacrificed and viable counts performed on homogenates of their lungs, to determine 
the size of inoculum which had seeded in the lungs of the exposed mice. The results are 
shown below in Table 6.3.5.1.
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Table 6.3.5.1 Initial colonisation In the lungs of mice Inoculated with an aerosol of
B. pertussis
On days 7 and 11 after challenge, three mice per group were sacrificed and viable counts of 
B. pertussis in the lungs of the mice were determined, as described in 6.2. The  results are 
shown in Table 6.3.S.2. Previous work (Roberts etal., 1990) had shown that, with the size of 
inoculum used, assaying at these time points should establish if any protection had occurred, 
being around the peak of bacterial growth in the lungs of unimmunised mice. Unfortunately, 
there was considerable intra-group variation in the counts. This, coupled with the small size of 
the groups, makes it difficult to interpret the data.
It would appear that no protection was afforded by inoculating mice intranasally with peptide 
683/KLH conjugate (group 7) relative to those mice inoculated with a  mixture of irrelevant 
proteins (group 8). Similarly, no protective effect was apparent in those mice given partially 
purified LT-B69 intranasally, with or without G M1 pre-treatment (groups 3 and 4 respectively), 
although in the latter case 3/6 mice were not detectably colonised at the time-points studied.
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Table e.3.5.2 Colonisation of the lungs of mice 7 and 11 days after challenge with
an aerosol of B. pertussis
Group
Mean cfu/anlmal (1 S.D.)
Day 7 Day 11
1 4 .6  (3 .7 ) X If f1 2.3 (0.7) x 10*
2 < 1 .1 1 (1 .0 ) x  10* 2.5 (2.7) x 10*
3 4 .6  (3 .1 ) X 10* 5.4 (7.0) x 10*
4 < 1 .5 a (2 .5 ) x 10“ < 5 .3 ' (8 .4 ) x  10*
5 < 5 .0 2 (9 .0 ) X 10s < 2 .0 ' (2 .0 ) x  10s
6 < 3 .0 2 (4 .0 ) x 10* 2 .0  (1 .8 ) x 10*
7 1.9 (0.6) x 10* 3 .3  (3 .3 ) X 10*
8 1 .6  (1 .3 ) x  10* 3.1 (1 .6 ) X 10*
\  1/3 mice without detectable numbers of bacteria 
2, 2/3 mice without detectable numbers of bacteria
Counts were performed as described in Section 2.10.3. Serial tenfold dilutions in PBS were 
made of the lung homogenates. Five replicate 50pl drops were added to the surface of a C W  
blood agar plate (containing streptomycin) and colonies counted after 3-5 days incubation. The 
mean cfu/animal for each group was then determined. A "less than" symbol is included where 
no colonies were detected in any of the replicate drops from one or two mice in that group.
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It might be argued that protection is apparent in group 6 (G y, pre-treatment, LT-B69 plus C T  
I.N.) at the earlier time-point, with only 1 mouse colonised and by comparatively low numbers 
( - 5  fold fewer than the mean value for group 8). However, no significant protection against 
colonisation is obvious at day 11. It would seem that only group 5 is consistently protected (L T - 
B69 plus C T  I.N., no Gy, pre-treatment), with only a total of 3/6 mice colonised on the two time- 
points. A t day 7, the mean count is more than 3 fold less than the control group and at day 11 
there is over 1 k>g10 difference between the counts. It may be significant that the highest levels 
of P.69-specific serum antibody were observed in group 5 (Figure 6.3.4.2)
W hilst there is good evidence for protection in only 1 group (i.e. group 5), it seems 
suggestive, when viewing the results as a whole, that the lowest degree of colonisation 
occurred among those groups which received the fusion protein I.N. with C T  (groups 5 and 6) 
or intramuscularly with C T  (group 2), that is, in those groups with the greatest P.69-specific 
lung A S C  and/or serum antibody responses. This would suggest that the BB05 epitope can 
stimulate a protective immune response if immunisation involves a suitable adjuvant. Previously 
it has been shown that immunisation with P.69 can protect mice against intracerebral 
challenge, and that passive immunity can be mediated by the transfer of BB05 mAb (Novotny 
et at.. 1985). Thus the results presented here would imply that responses to the BB05 epitope 
can also protect mice against an aerosol challenge. Ideally, to confirm these findings, such an 
experiment should be repeated with larger groups to reduce the significance of intra-group 
variation. However, these results are consistent with the recently published work of Charles and 
his colleagues (Charles et at., 1991). In their study, a fusion was made between the gene 
specifying the hepatitis B virus core antigen (HBcAg) and synthetic oligonucleotides encoding 
amino acid residues 537-566 of P.69. The  resulting fusion protein was expressed in yeast, 
purified and used to immunise mice intramuscularly. Mice treated in this way had viable counts 
of B. pertussis 10 fold lower than mice immunised with HBcAg alone. This protective effect was 
enhanced by the inclusion of incomplete Freund's adjuvant in the inoculum.
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6.4 Summary
6.4.1 The mechanism of protection
As the degree of protection achieved was very limited it is difficult to say with confidence what 
the mechanism of protection might be. However, numerous other reports have shown a strong 
correlation between immunity to P.69 and protection from disease in mice infected with B. 
pertussis (Novotny et at., 1985, Shahin et at , 1990b, Charles et a/., 1991 and Fairweather et 
al., 1990). There are two questions which are of interest; is protection a result of local or 
systemic immunity (or a combination of the two)? and what is the effector mechanism of the 
response?
6.4.2 Local or systemic immunity?
As the strongest evidence of protection is seen in group 5 (inoculated with LT-B69 fusion 
protein together with C T )  and to a lesser extent in group 6 (pre-treated with Gy, and then 
inoculated with LT-B69/CT), one might conclude that, when using LT-B69  as an immunogen, 
intranasal immunisation is necessary to protect mice against aerosol challenge, suggesting that 
local responses are most pertinent. This would agree with the observation that P.69-specific 
A S C  could only be detected in these groups. However, at day 11, there is little difference 
between groups 1,2 and 6, with regard to colonisation by B. pertussis, the former groups 
having been inoculated intramuscularly. It should be remembered that the two arms of the 
immune system do not operate in a  mutually exclusive manner. Thu s a case could be made 
for the involvement of systemic responses, a position which is supported by the serum antibody 
levels of the respective groups. Significantly, it has been found that in mice immunised sub­
cutaneously with recombinant P.69 purified from E. coli, circulatory antibody specific for P.69 
can protect against lung colonisation following challenge with an aerosol of B. pertussis (M.
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Roberts, personal communication).
6.4.3 Possible effector mechanisms
As stated above, it has already been demonstrated that antibody directed against the BB05 
epitope can be protective against B. pertussis aerosol challenge in a mouse model. It is 
possible therefore that specific antibody, whether slgA or serum IgG , is the effective mediator 
of immunity in the experiment reported here.
In the aerosol challenge model, growth of bacteria is restricted to the respiratory tract. 
Systemic antibody, if it is to exert an effect on the course of the infection, must therefore leave 
the circulation and transudate into the tissues of the respiratory tract. There is evidence that 
i.v. administration of anti-P.69 monoclonal antibodies can lead to their detection in the lungs 
within 1-6 hours (Shahin et al., 1990b) and can protect infant mice against aerosol challenge.
There are at least two mechanisms of protection one could envisage. P.69 is known to be 
surface-exposed (Charles et at., 1989) and has been shown to play a  role in the binding of B. 
pertussis to human epithelial cells (HEp2 cells) in vitro (Roberts etal., 1991). P.69 contains an 
arginine-glycine-aspartate (R GD) tripeptide sequence which has been implicated in the binding 
of mammalian cells to P.69 (Leininger-Zapata et at., 1989). Such RG D  motifs have been 
demonstrated to play a role in the binding of several other proteins to their receptor molecules 
(e.g. Ruoslahti, 1988; Fox et al., 1989). Thus it is possible that antibody binding to P.69 may 
cause a structural rearrangement or result in steric hindrance, leading to inhibition of binding 
to the host epithelium. However, recent evidence suggests that P.69 appears to be irrelevant 
to infection of the murine respiratory tract by B. pertussis (Roberts et al., 1991): insertion 
mutants of B. pertussis, defective for P.69 expression, were able to colonise mice as efficiently 
as the parental strain following aerosol inoculation. It seems unlikely therefore that P.69-specific 
antibodies protect by preventing adherence to host respiratory tract epithelium cells, at least 
in mice. An alternative explanation is that binding of antibody may result In opsonisation, with
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improved phagocytosis of the bacteria by those phagocytic cells with F . receptors (such as 
alveolar macrophages), or may lead to complement-mediated lysis of B. pertussis cells.
6.4.4 Improving the protective efficacy of LT-B69
As mentioned in section 6.3.4.2, LT-B69 contains no T  helper cell epitopes from  P.69. Clearly, 
this represents one way in which the protective efficacy of LT-B69 could b e  enhanced. Such 
an approach has already been employed successfully to increase the antibody response to a 
peptide epitope from foot and mouth disease virus (FM DV), (Francis et a!., 1987a,b). 
Furthermore, there is no reason why the T  helper cell epitope should have to be derived from 
P.69; any B. pertussis T  helper cell epitope might suffice as long as the B  cell and T  cell 
epitopes are present on the same immunogenic structure (i.e. in this instance, on the same 
bacterial cell). This phenomenon ("inter-molecular -  intra-structural help") h as been described 
previously for influenza virus (Russell and Uew, 1979) and hepatitis B virus (Milich eta!., 1987) 
and such a mechanism might well be operable where the structure is a bacterium rather than 
a virion. Candidate H LA  class ll-restricted human T  cell epitopes have been  described in the 
S1 subunit of pertussis toxin (De Magistris et al., 1989). The one major constraint on this 
approach is that the resulting fusion protein must still be capable of binding G ^ .
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C H A P T E R  7
General Discussion
7.1 Summary
It has been established by a number of workers that the immunogenicity of certain peptides, 
when administered to mucosal surfaces, could be enhanced by the addition or chemical 
coupling of C T -B  or L T -B  to the peptide sequence (see 1.7.1). Furthermore, a number of 
plasmid expression vectors have been constructed which allow genetic fusions to be made to 
C T -B  or L T-B . However, the fusion proteins which are expressed from such plasmids are often 
sub-optimal because they do not retain the properties of native LT-B , being unable to 
pentamerise or bind to G M1, the toxin receptor - characteristics which are probably a 
prerequisite for maximum immunogenicity.
This thesis describes the construction of an L T -B  fusion protein expression plasmid, which 
incorporates several features (e.g. the use of codons comparatively rarely utilised by E. coll) 
designed to allow insertion of oligonucleotides encoding peptide sequences at the 3' end of the 
L T -B  gene such that the resulting fusion protein is more likely to retain the properties of native 
LT -B . A  number of such fusion proteins were produced and all, including the largest fusion 
protein (comprising a 31 amino acid residue C  terminal extension), were found to form 
pentameric structures, be transported to the periplasmic space of E. coli and to retain affinity 
for G,,,.
Additionally, data presented here show that the fusion of L T -B  to a peptide sequence can 
exert a mucosal adjuvant effect after intranasal inoculation of mice, resulting in both increased 
serum antibody levels and a greater local antibody-secreting cell response compared to 
immunisation with the peptide conjugated to an inert carrier protein (KLH).
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Recently, Sixma et a/., (1991) published a putative three-dimensional structure for porcine LT, 
based on X-ray crystallographic studies. This is shown below in Figures 7.2.1-2.
Th e  L T -B  monomers were found to consist of one short amino-terminal a  helix (residues 
5-9), a large central a  helix (residues 59-78) and two three-stranded p sheets. These 
monomers are arranged in a circle around a central pore, much as earlier models predicted 
(Sigler et al.. 1977). Th e y  are so positioned that the p sheets of one monomer lie adjacent to 
the p sheets of its neighbours. The central pore is bounded by many charged amino acid 
residues (e.g. arginine, lysine) and numerous salt bridges are believed to be formed between 
these and the charged amino acid residues present in the A2 domain of the A-subunit, which 
inserts into the pore.
This model is particularly attractive because it explains several experimental observations. 
For instance, although degraded by boiling and low pH, the pentameric L T -B  is reasonably 
stable in a range of environmental conditions. In the model of Sixma etal., (1991) over 1/3 of 
the surface area of each monomer is buried by pentamer formation. This figure is higher than 
most comparable multimeric proteins and probably contributes to the observed stability. Despite 
this strong association between monomers, only a small number of interactions is believed to 
occur. According to the current model, one such interaction is between alanine at position 64 
in one monomer polypeptide and a methionine residue at position 31 in an adjacent monomer. 
This would explain the finding of lida et al., (1989) that a single mutation (ala 64 - » val 64) at 
this position can inhibit pentamerisation.
Furthermore, the Gy,-binding site in the present model is thought to reside in a pocket, 
which is formed by amino acid residues derived from adjacent monomers. This agrees with 
previous suggestions (e.g., lida et al., 1989) that L T -B  must be in multimeric form to bind to 
G *,. This is supported by the results obtained in this study concerning the affinity for G*, of 
boiled and unheated samples of partially purified LT-B69.
7.2 The structure of L T  -  a rational basis for empirical observations
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B( 2 )
Figure 7.2.1 A  schematic diagram of the secondary structure of the L T -B  subunit and its 
pentameric arrangement, a,residues 5-9, P,:15-22, p2:26-30, p,:37-41, p«:47-50, 0^:59-78,
P5 82-88, pe:94-102. Numbering of the B-subunits is anti-clockwise when viewed towards the 
A-subunit (reproduced from Sixma el a!., 1991).
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Figure 7.2.2 The three-dimensional structure of L T  holotoxin. CA1 represents the last residue 
of the A1 subunit, NA2 the first residue of the A2 subunit. N and C  show  the positions of the 
amino and carboxyl termini respectively of the five B-subunit monomers. 88 represents the 
location of residue trp88, believed to comprise part of the G M1-binding pocket (reproduced from 
Sixma et al.. 1991).
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7.3 The structure of L T  • implications for the improved design of LT -B  fusion proteins
If the model of the L T -B  pentamer proposed by Sixma eta!., (1991) is substantially correct, the 
amino-termini of the L T -B  monomers are buried within the pentamer, whilst the carboxy-termini 
are at the ’bottom” of the molecule and point away from the structure. Thus the addition of 
extra amino acids to the N-terminal might well abolish G^-binding ability by preventing 
pentamer formation whereas, because of the location of the C-termini, extensions can be made 
at these points without interfering with B-subunit -  B-subunit interactions. This would support 
the observations made in this thesis concerning the G*, ,-binding properties of various L T -B  C - 
terminal fusion proteins. Thus, in the example of LT-B69, up to 31 amino add residues could 
be accommodated without a significant deleterious effect on G u,-binding.
Such extensions to the carboxy-termini probably would prevent association with the A- 
subunit (as experienced by Sandkvist et at., 1987) due to steric hindrance interfering with the 
normal interactions between the A-subunit and the B-subunit pentamer (see Figure 7.3.2). 
However, in the context of potential use as mucosal adjuvants free from toxicity, this does not 
constitute a disadvantage. It is clear that C-terminal additions, within certain limits, should also 
permit LT-B/ganglioside interactions to take place unimpeded; the proposed G M,-binding pocket 
is a considerable distance (in molecular terms) from the caiboxy-terminal of the monomer.
Thus the C-terminal offers several advantages as a location for the addition of heterologous 
epitopes, which can be readily effected by the insertion of relevant D N A sequences at the 
unique Spei site at the 3' end of the L T -B  gene. One other favourable location for the 
accommodation of heterologous epitopes might be the surface-exposed loop, represented by 
residues 50-64, which has already been found to be immunogenic (Jacob et al., 1985).
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7.4 Future developments
One possible development to exploit immunogenic L T -B  fusion proteins is to express them in 
suitable bacterial hosts, such as attenuated strains of Salmonella spp., which have proven 
efficacy as experimental oral vaccines. Such an approach has been described both in this 
thesis and by other researchers (SchOdel et al., 1990a,b) but the results have been rather 
disappointing thus far. It might be that synthesis within a bacterial vector alters the nature of 
the initial interactions between the L T -B  fusion protein and the immune system. Thus, rather 
than the LT-B  fusion protein being absorbed across a mucosal epithelium into, for example, 
Payer's patches or bronchus-associated lymphoid units after oral or intranasal inoculation, the 
first interactions between the immune system and L T -B  present in the periplasmic space of 
Salmonellae might occur with macrophages in the R E S  which phagocytose the bacteria. This 
might influence the ensuing immune response. Thus whilst expression in vaccine strains of 
Salmonella spp. may be suitable for stimulating good cell mediated responses to a  particular 
immunogen, it is not necessarily ideal for all LT -B  fusion proteins if they possess intrinsic 
mucosal immunogenicity.
An alternative approach might be to involve the holotoxin in some way; nearly all the 
comparative studies which have been described show that C T  is more immunogenic than C T -B  
(Pierce, 1978, Lange etal., 1978, Lycke and Holmgren, 1986, Chen and Strober, 1990 and van 
der Heijden et a i, 1991). Presumably the same is true for L T  and LT-B . It would seem highly 
desirable therefore if one could produce an altered form of toxin A-subunit which retained 
immunological activity without toxicity, comparable to the Cross Reacting Material (CRM) 
mutant forms of diphtheria toxin (Pappenheimer et al., 1972, UchkJa et al., 1973) and pertussis 
toxin (Pizza et al., 1989). This would have considerable potential as an adjuvant for vaccines 
delivered orally or intranasally. However, as explained previously, toxin B-subunits extended 
at the C  terminal are unlikely to associate with A-subunit due to steric hindrance. Thus a 
modified non-toxic A-subunit would have to be added as exogenous holotoxin (with native B- 
subunits) rather than as an integral part of a holotoxin with chimeric B-subunits. (Alternatively,
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it might prove possible to engineer the modified non-toxic A-subunit such that it can associate 
with chimeric B-subunits).
One of the first examples of such an approach was described by Rnkelstein eta!., (1971) 
who produced "procholeragenokT -  a stable, high molecular mass aggregate of A- and B- 
subunits, formed by heat-treatment of C T. Procholeragenoid had only 5 %  of the toxicity 
associated with C T  but was still highly immunogenic when given to mice orally (Fujita and 
Finkelstein, 1972). However, this level of toxicity is unacceptable for use in human vaccines.
Similarly, Liang et at, (1989) demonstrated that glutaraldehyde treatment of C T  could 
diminish toxicity about 1,000 fold whilst the toxoid generated in this way retained some 
immunogenicity. However, this was still far from ideal because toxicity was not totally abolished 
and the adjuvant activity was substantially curtailed. Recently, Tsujl e ta i,  (1990) reported their 
findings concerning a hydroxylamine-induced mutant form of L T . D N A sequence analysis 
revealed a single base change, resulting in one amino acid substitution in the A-subunit at 
position 112 (glu112-»lys112). This mutant had greatly reduced toxicity but the mucosal 
immunogenicity or adjuvanticity of the molecule was not described. It may well be that an 
effective compromise between toxicity and adjuvanticity proves exceptionally difficult to obtain 
as it seems that adenylate cyclase activation is an intrinsic part of both the toxin and adjuvant 
mechanisms. However, the recent determination of the structure of L T  (Sixma et a!., 1991) 
should allow for a more rational approach (e.g. the logical application of site-directed 
mutagenesis) which should facilitate the task.
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